I I I I I II I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I II I I I I I II I I I I I I II I I I I I I II I I I I I I II I I I I I I I I I I I I I I II I I I II II I I I I I I II I I I I I II I I

Garvan InstituteGarvan of Medical Research Garvan Institute of Medical Research Annual Report 2008 Annual Report 2008 I I I I I I I

II Garvan's mission is to make significant contributions to medical I II research that will change the directions of science and medicine and I I

II have major impacts on human health. Garvan strives to enhance and I I

II develop research programs that combine fundamental science with I I strong clinical interactions. I I I I I I I II CONTENTS

_ 03 Who We Are, What We Do

_ 04 Research Highlights

_ 07 Garvan at a Glance

_ 10 Chairman's Report

_ 12 Executive Director's Report

_ 14 Garvan Research Foundation Chairman's Report

_ 17 Organisational Chart

Research Programs _ 19 Cancer _ 27 Diabetes and Obesity _ 33 Immunology and Inflammation _ 39 Osteoporosis and Bone Biology _ 43 Neuroscience _ 47 Autoimmunity Research Unit _ 51 Pituitary Research Unit

_ 55 Core Research Facilities

_ 57 Management Highlights

_ 59 Business Development

Garvan Community _ 60 Life Governors _ 60 Partners for the Future _ 60 Volunteers _ 61 Garvan Supporters _ 63 Bequests

Governance _ 65 Institute Governance _ 67 Foundation Governance

_ 72 Publications

_ 81 Financial Highlights

IIII 03 WHO WE ARE, WHAT WE DO WHO WE ARE, WHAT

Significant breakthroughs have been breakthroughs Significant achieved by Garvan scientists in the of diseases and treatment understanding such as: _ Cancer and obesity _ Diabetes disease _ Alzheimer's and Parkinson's _ Osteoporosis _ Arthritis and asthma _ Pituitary disorders and Garvan's goal is prevention ultimate of these major diseases. cure The Garvan Institute of Medical Research is a world leader in its The Garvan Research of Medical Institute diseases some of the most widespread field, pioneering study into at Garvan upon is focused Research affecting today. our community in health and disease as the basis of genes the role understanding cures. developing future for WHO WE ARE, WHAT WE DO ARE,WHO WE WHAT IIIIIIIII I I I I I I I I I RESEARCH HIGHLIGHTS

_ Diabetes researchers found a significant missing link in our knowledge about insulin and how it helps cells absorb glucose. We showed that insulin activates a 'motor protein' that in turn drives glucose transport molecules to the cell surface. _ Our Dubbo Osteoporosis Epidemiology Study demonstrated that low levels of testosterone in men double their risk of bone fracture; that men with prostate cancer face a 50% higher risk of fracture, which increases to nearly 100% if they are receiving androgen deprivation therapy; and that osteoporotic fractures increase a person's risk of dying, even after relatively minor fractures if that person is over 75. The Osteoporosis and Bone Biology Program also devised a web-based fracture risk calculator, which has been widely adopted by the medical community throughout Australia. _ To remain healthy, we must maintain exactly the right number of B cells, the white blood cells that produce antibodies. Garvan immunologists identified two proteins made inside B cells, TRAF2 and TRAF3, that are essential for maintaining this important balance within our immune systems. When the balance fails, we become prone to developing certain cancers or autoimmune diseases. _ An international team of scientists from Garvan, Harvard Medical School and the Max Planck Institute in Germany, identified processes that are heavily implicated in human multiple myeloma and other B cell cancers, moving us closer to developing quick tests and readouts that could help in the tailored treatment of patients. _ Neuroscience researchers showed that a hormone released naturally from the gut after a meal could be used to treat obesity and Type 2 diabetes. The hormone peptide YY (PYY) acts on the brain, contributing to a feeling of satiety, suggesting the use of this hormone as a weight loss medication. _ Researchers concluded that low levels of PYY could be used as a predictor for the development of Type 2 diabetes. Clinical studies showed that people with a family history of Type 2 diabetes, but not yet showing signs of insulin resistance themselves, produce lower levels of PYY after eating, a very early sign of pre-diabetes. _ Cancer researchers found that by 'switching off' the Id1 gene, produced by the most aggressive forms of breast cancer, it is possible to induce a state of 'senescence', or permanent sleep, within a tumour, preventing it from growing or spreading. _ Garvan and CSIRO signed a three-year collaboration agreement to investigate important cellular processes, including those impaired by diseases such as diabetes. They will be using a new computer vision system they developed jointly to watch intricate cellular processes in real time. _ Immunology researchers working on Type 1 diabetes uncovered a process with the potential to alter the body's response to anything it perceives as not 'self', by stimulating the production of a class of immune cells known as T regulatory cells. The finding gives us hope that one day it may be possible to alter the immune system to accept tissue transplants without the need for any immunosuppression. I I I I 04 RESEARCH HIGHLIGHTS IIII 05 RESEARCH HIGHLIGHTS Nature article about the global taskforce taking shape for the human epigenome the human for shape taking article the global taskforce about Nature Epigenome of the Australian members is one of the founding Clark project. Professor in 2008. formed Alliance, operates of leukaemia. Gab2 forms and certain cancer that trigger breast processes of the drug HER2, the target oncogene, cancer breast of a major downstream Herceptin. four and extracted a Chinese vegetable, melon, bitter of fresh a tonne pulped roughly used in Chinese why it is has been bioactive that explain very components promising Type for be an effective treatment to years. It now promises of hundreds medicine for 2 diabetes. or Garvan out why people with Hyper IgE Syndrome, immunologists worked Research, By revealing infections. common certain to unusually susceptible are 'Job's Syndrome', why some given clues as to molecular mechanisms involved, theythe exact were than others. these infections to prone more 'healthy' people are effect' in sport. using a performance-enhancing 'placebo believe they are athletes If even if they are and in some it can, improves, drug, they may think their performance actually a dummy drug. taking in our Diabetes Researchers types similar in both of diabetes. were cells pancreatic diseases. They in the two also different is quite that the process showed Program 2 diabetes. with Type people for target therapeutic identified a promising Garvan is very yet complex, have discovered immunologists The process infection. without which it factor, a growth as IL-21, that it hinges on a single molecule known defences. the body's natural strengthen function. to ways This finding suggests cannot outcomes, clinical genes with predictable oestrogen-regulated functionally-related good will make cancer breast with should help clinicians decide which women and which will not. such as tamoxifen, therapies, anti-oestrogen for candidates in our and heart researchers by clinical disease. A study diabetes to susceptible more Immunology, for Centre with St. Hospital's Vincent's in collaboration group, Diabetes patient management and why - enabling better of the reasons some showed monitoring. some reactions allergic the extreme for that may account and IL-21, molecules, IL-4 one of these molecules, it may be possible to By silencing at least people experience. allergies. treat find the genes to multi-nation genome-wide search in an extensive deCode, company, identified that appear were of interest Five regions and fracture. osteoporosis to linked further investigation. scientific warrant to an important be to that is likely made a finding Institute IDI Heart and Diabetes a insulin resistance, the mechanisms of obesity related in understanding milestone help to protein one important They have manipulated 2 diabetes. of Type precursor muscle burn fats. _ Garvan epigenetics expert, Professor Susan Clark, was the Australian contributor to a to contributor the Australian was Susan Clark, Garvan_ epigenetics expert, Professor in the molecular off' protein Gab2, a key 'switch to identified a way researchers Cancer _ Medica of Materia Institute and the Shanghai Garvan's Program from Diabetes Teams _ John Curtin School of Medical Canberra's from with researchers In collaboration _ the Unit demonstrated in our Pituitary Research by researchers undertaken A study _ the death of insulin-secreting to leading thought that the processes it was now, Until _ of potent, or 'high affinity', on the production fight antibodies to bodies rely Our _ of certain expression correlating Program, the Cancer within work Seminal _ much HIV also become for that people treated some time Clinicians have known for _ two between encounter a synergistic identified a process, Immunology_ researchers and Bone Biology ProgramThe Osteoporosis _ genetics with the Icelandic collaborated with Melbourne's Baker in collaboration Program, in our Diabetes experts Metabolic _

IIII 07 GARVAN AT A GLANCE AT GARVAN GARVAN AT A GLANCE AT GARVAN

IIIIIIIII Collaborations Research Patent Portfolio by Category

New treatments 23% Drug discovery tools 10% Therapeutics 3% New drug targets 23% Diagnostics 41%

190

180 185 Scientific Publications 160

153 140 151 Impact factor of scientific publications 135 120 Each paper published constitutes a new piece of knowledge, and scientists aim to publish in the most highly regarded journal in their area of research. 115 100 Each journal has an “impact factor” which is a common measure of its relative 104 80 importance within a specific discipline. Research organisations use “average impact factor” measurements to determine the overall significance of their 60 research output. For example, in 2008 Garvan achieved an “average impact factor” greater than 8 for the top 75% of its publications. This is a very 40 respectable tally, well above the international benchmark. 20

0 Number of Publications 2003 2004 2005 2006 2007 2008

7 Growth in Philanthropic Support

6 Total Income Donations are particularly important 5 (excluding bequests) in two respects: received by Garvan _ They provide seed funding for 4 Research Foundation novel work, which may not attract other support for several years 3 $3,539,000 _ They fund core items of equipment 2 $2,790,000 that are typically not covered by $4,158,000 research grants 1 $5,370,000

0 Income $ mil Income $6,966,000 2004 2005 2006 2007 2008 I I I I 08 GARVAN AT A GLANCE 500 Growth in Staff Numbers 479

400 433 403 _ Average age 38 Staff Breakdown 2007 2008 373 _ Researchers from 55 countries Researchers 301 314 300 308 291 _ Research staff 61% female, Students 61 68 39% male Scientific Facility Staff 44 62 200 Secretarial & Administration 27 35

100 Total 433 479

0 Number of Staff 2003 2004 2005 2006 2007 2008

…: Operating Income

2008 $47 Million One of the major challenges facing successful research institutes around Competitive grants 61% Australia remains the “gap” between the Other grants 10% total costs of doing research and the funding provided by competitive research Donations 10% grants. For every dollar of research NSW Government 9% funding awarded, another 70 cents is required to carry out the research. Industry partners 2% Other income 8%

30 Peer Reviewed Grant Income

25 $ Mil $ Mil Our funding from the National Health and Medical Research Council (NHMRC) Year NHMRC Other 20 rose to a record $18.7m, up from 2003 8,465 5,636 $16.7m in 2007. Overall, peer reviewed 15 grant funding increased to 2004 9,244 6,222 approximately $27.9m. 2005 12,080 8,685 10 2006 13,832 8,184 5 2007 16,682 8,530 2008 18,695 9,159 0 Income $ mil Income 2003 2004 2005 2006 2007 2008 I I I GARVAN AT A GLANCE 09 I I I I I I I I I I CHAIRMAN’S REPORT

2008 Garvan continued its excellent record of research success in 2008, as measured by grants, publication impacts and international awards, and we are justly proud of our faculty and staff. Several important strategic initiatives came to fruition during the year, including: _ completion of a major review of the Institute's future directions by an international panel _ the opening of our major breeding and holding facility for experimental mouse models in the Southern Highlands (Australian BioResources), and _ rapid progress in development of plans for the new Garvan St Vincent's Campus Cancer Centre. Financial Performance Garvan's operating income grew to approximately $47m in 2008 from $42m the previous year, an increase that is testament to the quality of Garvan research. Philanthropic support through the Garvan Research Foundation, essential for providing critical equipment and facilitating new initiatives, continued to be strong, with over $4.7m in general and specific grants contributed to research programs and almost $4.0m into the long term endowment of the Institute. Our People Once again my sincere thanks and admiration are extended to Professor John Shine, his senior management team, faculty and staff. I am also most grateful for the commitment and counsel of the Board of Directors. The only change to the composition of the Board during the year was the resignation of Ms Mary Foley, following her retirement from the position of Chief Executive of St Vincents & Mater Health. During her tenure on the Board, Ms Foley championed the close relationship between Garvan and St Vincent's. We welcomed the new CEO of St Vincents & Mater Health, Mr Steven Rubic, to the Board in the latter part of 2008. Strategic Review In 2008, the Board commissioned an independent review of the Institute's programs and directions, assembling a review panel of leading international scientists for this important task. Chaired by Professor Bruce Dowton, former Dean of the UNSW Medical School and now Senior Vice President at Harvard Medical International, the panel completed its work midway through 2008. This provided a valuable strategic framework for management and Board in setting future directions for the Institute. The Board endorsed the recommendations of the Review and I am pleased to advise that the implementation process is already well underway. I I I I 10 CHAIRMAN'S REPORT IIII 11 CHAIRMAN'S REPORT AC Chairman Garvan Research of Medical Institute Bill Ferris Bill Ferris The Review confirmed the importance for Garvan of focusing its efforts on a few on Garvan its efforts for of focusing the importance confirmed The Review and competitive. relevant internationally remain expect to it can where themes research this immunology and into disorders all fell neurobiological diabetes/metabolism, Cancer, and work emphasis on translational an increasing encouraged The Review category. Garvan Campus Centre. Cancer Vincent's of the proposed St the importance confirmed down by breaking culture its Institute-wide Garvan strengthen to also urged The Review management and new governance some important silos”. Accordingly, “research in Director by the Executive outlined and are been implemented have already structures this report. CampusCancer Centre Garvan Vincent's St gained project GarvanDuring 2008, the $100m Campus Centre Cancer Vincent's St on the development of the completed was work momentum. Extensive significant were we Importantly, functional and the appointment of architects. and design briefs support the of nearly $20m plus major philanthropic in attracting also successful Hospital. Vincent's of St the Trustees of the land from commitment in practice best and world's standing of international a facility create The vision is to can at which new discoveries the rate which will accelerate research cancer translational and researchers clinical clinicians, will bring together be trialled in the clinic. The Centre via the patient outcomes improve to the campus, across from scientists biomedical of cancer. treatment diagnosis and detection, Business Development research in translating by progress is being matched in basic research Garvan's success patients. for outcomes real into “discoveries” As this 2 diabetes. Type for novel treatment involves a potential One important project enough insulin secrete to fail pancreas of the cells develops, the beta disorder debilitating that the have discovered Garvan's researchers diabetes sugar. levels of blood regulate to and that in this process role plays a central kinase C epsilon (PKCe) enzyme, protein we Accordingly, in insulin secretion. improvement in a marked results inhibition of PKCe new evaluate to group with a US based pharmaceutical an agreement into have entered as are If the results indication. another trials for in clinical already inhibitors, PKCe potent expect,clinic in a short the positive as we timeframe. should enter the compounds 2009 particularly the the ongoing challenges of expansion, anticipate In the year ahead, we Important the cancer new initiatives, such as on infrastructure. pressure continuing in financial and human resources. a major increase will also require centre, that, is confident our with the supportThe Board of government and the community, impact on human health, particularly have a growing we as to will continue research delivery. closely with health care it even more integrate I I I I I I I I I EXECUTIVE DIRECTOR’S REPORT

2008 was another outstanding year for Garvan in terms of significant research findings, success in obtaining competitive grants and growth in the number of papers accepted for publication in prestigious international journals. We published 185 peer reviewed research papers, the top 75% in journals with an average impact factor greater than 8. This remains above internationally accepted benchmark levels and is testament to the excellence and commitment of our researchers. Research publication productivity was matched by success in applications for competitive grants. Our funding from the National Health and Medical Research Council (NHMRC) rose to a record $18.7m, up from $16.7m in 2007. Overall, peer reviewed grant funding increased to approximately $27.9m. Of particular importance was our success with NHMRC Program grants for both the Cancer and Diabetes and Obesity Programs. Together with renewal of a similar Program grant for the Immunology Program in 2007, three of the Institute's major research programs now have guaranteed high-level support for the next five years. This allows us to think more strategically long-term. Staff numbers across the organisation continued to grow to a total of 479. Growth was particularly strong in our Cancer, Immunology and Diabetes and Obesity Programs, reflecting ongoing success in competitive grant applications for new and existing projects. Australian BioResources (ABR) The state-of-the-art holding and breeding facility for experimental mice lines at Moss Vale provides critical infrastructure for Australian innovation. Experimental mouse-based models underpin modern medical research and biotechnology, their use growing exponentially in recent years. As a result, medical research institutes and universities are increasingly challenged to find the resources to house and provide expert care and specialised breeding and laboratory services for the rapidly expanding colonies. This situation threatens to compromise our internationally competitive research and hold back innovation in the sector. The facility is now fully operational and already proving to be a success, fulfilling the needs of Garvan and its initial partners across NSW. At the end of 2008, ABR held nearly 20,000 mice, a number expected to double over the next few years. Campus Developments An active member of the St Vincent's Campus, Garvan values its historic and ongoing close association with St Vincent's Hospital and its commitment to the values of the Sisters of Charity. During 2008, the new Lowy Packer Building for Victor Chang and St Vincent's research was officially opened, providing state-of-the-art research accommodation for over 200 researchers. Like the Garvan building, the new building will house several core research facilities shared by all research groups on the Campus. With the decanting of Victor Chang and St Vincent's researchers from space previously occupied in Garvan, we have refurbished the area to increase available research space and accommodate new technologies. I I I I 12 EXECUTIVE DIRECTOR'S REPORT Our joint venture with St Vincents & Mater Health to establish the Garvan St Vincent's Campus Cancer Centre made major progress in 2008. Garvan researchers and St Vincent's clinicians are united in their enthusiasm for this unique opportunity to translate our research “discoveries” into improved treatment and prevention of cancer. 2009 Last year a major review was carried out examining the future directions of Garvan's science and optimal structure to facilitate ongoing success. This has helped shape our thinking and planning over the next decade. We have already implemented some important changes to our management structure to help address the challenges of growth and the increasing cross-Program nature of our research endeavours. Specifically, we have created an Executive Research Committee as the major policy and strategic advisory body of Garvan. Chaired by the Executive Director, the committee includes leading researchers at varying stages of their careers, allowing a broad spectrum of Garvan researchers to help chart our future. Other important initiatives follow the Review, including the establishment of an Operations Committee, chaired by the Chief Operating Officer, charged with enhancing communication between our ever increasing research base and the professional support functions essential for the effective operation of the Institute. We have also reconstituted our Scientific Appointments and Promotions Committee to include additional external members as the breadth of our research activities expand. Similarly, we are appointing a Scientific Advisory Council of eminent international and national researchers to help advise the institute on current and future research directions. I look forward to reporting on the detail and successful outcomes of these new structures in future years, as Garvan evolves to take maximum advantage of the enormous opportunities to improve quality of life that are evident in today's medical research. Reinvigorated by the success of 2008 and strengthened by the outcomes of the Review, we will remain clearly focused on elucidating the fundamental basis of disease. We will also drive the translation of our research discoveries into new and improved ways to prevent and treat the major diseases that challenge our society.

John Shine AO FAA Executive Director Garvan Institute of Medical Research I I I EXECUTIVE DIRECTOR'S REPORT 13 I I I I I I I I I I CHAIRMAN’S REPORT Garvan Research Foundation

I am delighted to report that the Foundation's results have exceeded expectations in 2008 by over $2.0 million, with total income of $10.2 million - an exceptional performance, particularly in this economic climate. Total gift income excluding bequests was $7.0 million, as against $4.2 million in 2006 and $5.4 million in 2007, continuing the growth trajectory initiated by our CEO when she took up the role three years ago. Bequests this year totalled $3.1 million. It is impossible to overstate the significance of such gifts, often enabling us to put in place a 'next generation' program or core research infrastructure. The Foundation grew its annual grant to the Institute to $926,000 and contributed $3.8 million to specific research programs or projects. We also added nearly $4.0 million to the Institute's endowment fund. Major gifts We thank our major donors (some of whom choose to remain anonymous) for their loyalty and support of our research programs. Ms Rosemary Pryor gave $1 million to fledging projects in Neuroscience (work that requires up to three years of philanthropic funding before it is possible to apply for competitive peer-reviewed grants). Mrs Virginia Kahlbetzer continued her crucial support ($200,000 per year) for our lung cancer research. Stalwart corporate supporter, the MLC Community Foundation, pledged $1 million over five years, to support one of our core scientific facilities. New corporate supporter, graysonline.com, committed $200,000, enabling the purchase of a key piece of scientific equipment. Graysonline.com also auctioned jewellery from the Drs Ryan's estate, helping us raise nearly $60,000. The John T Reid Charitable Trusts donated funds to support a new microscope for the Molecular Imaging Unit, accessed by researchers at Garvan, across the campus and at other research enterprises. Mr Trevor and Mrs Christina Kennedy contributed the majority of their $1.0 million gift to hearing loss research in 2008. Lady (Mary) Fairfax also gave a further $500,000 to this research. Mr Paul and Mrs Judy Hennessy established the Stuart Furler Travel Fund. Stuart was one of the longest-serving researchers at the Garvan until he died of pancreatic cancer. The Fund will support young researchers' travel to international conferences and laboratories. I I I I 14 GARVAN RESEARCH FOUNDATION CHAIRMAN’S REPORT . AO IIII 15 and Mr Richard Warburton Warburton and Mr Richard AM GARVAN RESEARCH FOUNDATIONGARVAN CHAIRMAN’S REPORT , Mr Brad Rees, Mr Karim Temsamani and Mr Mr Karim Temsamani Rees, , Mr Brad AM , the Hon Warwick Smith , the Hon Warwick AM Events the opening of AGM, 2008, including the events in several managed The Foundation On 17 August, Open Day. and the Institute's Vale in Moss BioResources Australian information disease-focused showcasing Garvan visitors, over 900 its doors to opened and cancer; and a panel on diabetes presentations manned by our researchers; booths and medicine. Open Day of science discussing the future guests of distinguished year. run this event every second to intend and we excellent was feedback the 25-35 year old for forums three Garvan again delivered Committee Our Young research. of medical of the importance awareness raise helping to of Sydney, professionals Campus Centre Cancer The Garvan Vincent's St of the challenge CEO accepted business, the Foundation GarvanIn addition to core Garvan between the new joint venture for campaign leading the $100 million capital Campus Centre. Cancer the Garvan Vincent’s Health Sydney, St & Mater Vincents and St of the role who has accepted Goodrem of Ms Delta the generosity appreciate We in the role a key played and funds. Delta awareness with raising and assists Patron The Dinner raised and Gala Dinner held on 22 October. media conference $240,000. approximately $16 million pledged around privately approached supporters a few the Dinner, to Prior These the Centre. million to gave $5 example, for in 2008. The Kinghorn Foundation, appreciated. greatly gifts are very generous changes and staff Board their energy and vision, for Directors this opportunity thank my fellow to take I wish to in 2008. changes on the Board several note and to Directors: Mr Ross King, Mr of retiring acknowledge the contributions gratefully We Mr Phil Clark Wade, Peter A special thank you goes to Richard Warburton who served on the Board for 12 years. who served for on the Board Warburton Richard A special thank you goes to Mr Loftus Harris also welcome We Geoff Dixon to the Board. the Board. to Geoff Dixon We grow. to continuing changes in 2008, with the Foundation staff several were There Mona Saade as our years, and welcome thank Rachael Stewart, who left three us after Services new Supporter Coordinator. Lam, Data and Janice Manager, Media Relations Dianne Lavender, also welcome We including media coverage, Dianne achieved considerable EntryClerk. year, In her first about diabetes service and a community announcement stories, 7.30 Report two Hines. With 2,094 new donors joining Garvan Marcia to in 2008, in addition featuring position is essential. Janice's year, 1,500 the previous and deepening retaining to I thank each and every Garvan and look forward supporter with you in 2009. our relationship Bradley Graham Chairman Foundation Garvan Research I I I I I I I I I ORGANISATION CHART I Garvan Institute of Medical Research Board of Directors

Chairman Mr Bill Ferris AC

Executive Director Prof John Shine AO FAA

Development & Support Group Cancer Garvan Research Foundation Chief Operating Officer Mr John Dakin Leader Prof Rob Sutherland FAA Board of Directors Senior Scientists Chairman Mr Graham Bradley Australian BioResources Prof Sue Clark Dr Jenny Kingham Prof Roger Daly Garvan Research Foundation A/Prof Sue Henshall Chief Exec Officer Ms Carole Renouf Business Development & Legal Affairs Dr M Kohonen-Corish Ms Christina Hardy Prof Liz Musgrove Corporate Services A/Prof Chris Ormandy Autoimmunity Research Unit Ms Cate Smith Cancer Development Laboratory Leader Prof Fabienne Mackay Diabetes Vaccine Development Centre Prof Marie Dziadek Ms Rowena Tucker Senior Scientists Finance and Accounting Prof Antony Basten AO FAA Ms Cherry Dutton Diabetes & Obesity Dr Robert Brink Human Resources Leader Prof David James FAA Ms Deborah Pearson Senior Scientists Pituitary Research Unit Information Technology A/Prof Trevor Biden Leader Prof Ken Ho Mr Jim McBride Prof Lesley Campbell AM Operations Prof Don Chisholm AO Mr David Keenan A/Prof Greg Cooney A/Prof Antony Cooper Science Communications Prof Ted Kraegen Ms Alison Heather Dr Ross Laybutt A/Prof Katherine Samaras Board Committees Dr Carsten Schmitz-Peiffer _ Business Development Advisory _ Finance & Audit Core Research Facilities _ Investment Australian BioResources _ Remuneration Peter Wills Bioinformatics Centre Immunology & Inflammation Institute Committees Pieter Huveneers Molecular Imaging Unit Leader Prof Charles Mackay FAA Gene Chip Facility _ Appointments & Promotions Senior Scientists Biological Testing Facility _ BTF Policy Advisory Clinical Research Facility Dr Shane Grey _ Building & Equipment Flow Cytometry Facility Dr Jenny Gunton _ Director’s Executive Australian Cancer Research Fund Dr Cecile King _ Higher Degrees _ Information Technology Unit for the Molecular Genetics of Cancer Prof Jonathan Sprent FRS FAA Dr Stuart Tangye _ Occupational Health & Safety _ Publications _ Seminars Neuroscience _ Senior Scientists Leader Prof Herbert Herzog Campus Committees _ Animal Ethics Senior Scientists _ Human Research Ethics Dr Sharon Oleskevich _ Institutional Biosafety A/Prof Amanda Sainsbury-Salis _ Precinct Management Dr Bryce Vissel _ Precinct OH&S Garvan is a partner in the CRCs for Asthma and Biomedical Imaging Development. Osteoporosis & Bone Biology Garvan is a shareholder in the spin-out Leader Prof John Eisman AO company G2 Therapies Ltd. Senior Scientists Prof Tuan Nguyen Dr Paul Baldock I I I ORGANISATION CHART 17 I DNA samples on chips for epigenetic analysis. IIII 19 CANCER PROGRAM HOXA9 is methylated in almost all high in almost is methylated HOXA9 ovarian carcinomas, serous grade new diagnostic a potential representing these, the most common for marker type of ovarian cancer in particular that concordant lung cancer, 3p of the chromosome methylation genes, DLEC1 and MLH1, is associated survivalwith poorer of patients and cancer cells normal prostate that incorporates cells prostate and gene modifications epigenetic levels - allowing us to expression identify that regions novel genomic in cancer deregulated commonly are (its gene p16 is repressed suppressor proteins, into or conversion expression, (shut being methylated before reduced) cells down) in cancer the nucleosomes 'seeded' in between (the part of the region of its promoter of genome that triggers the expression to the gene) and then spreads silencing epigenetic consolidate _ Showed that the developmental gene the developmental that Showed _ for biomarkers new prognostic Identified _ a human epigenome map of Created _ that the tumour Demonstrated _ is initially that p16 methylation Found _ protein is necessary for the for is necessary protein developmentduring tissue of breast and that increased pregnancy drives mammary of Elf5 expression in development and milk production animals non-pregnant kinase, controls integrin-linked protein, normal mammary gland development suggesting in mice, and differentiation levels of the gene may have that altered progression in cancer a role 'sleep' state an irreversible be put into can by inhibiting the activity of the Id1 gene for biomarker as a predictive protein in pancreatectomy to response cancer pancreatic a feature are Gata2 factor transcription and may cancer prostate of aggressive the action influence of the androgen may be an Gata2 suggesting receptor, of advanced important regulator disease prostate the to of resistance biomarker in drug, docetaxel, chemotherapeutic cancer prostate _ Showed that expression of the Elf5 expression that Showed _ signalling that the cell Demonstrated _ in mice that mammary cancers Found _ the S100A2 calcium-binding Identified _ the that high levels of Demonstrated _ as a the MIC-1 protein Identified _ FAA

Professor Rob Sutherland Professor

Leader CANCER PROGRAM how oestrogen regulates the cell cycle the cell regulates how oestrogen by or proliferation) replication (cell of regulation showing that oestrogen cyclethe cell gene, cyclin D1, leads to activation of cyclin E2 persin, action toxin of the avocado the endoplasmic which acts through where of cells (the region reticulum kill to formed) are proteins complex cells cancer breast in the implicated a signalling protein cancers development of some breast is of leukemia, forms and certain in cells 'switched-off' at Adelaide's Hanson Institute, Kumar protein, that a regulatory determined the action of for Nedd4, is required and hence factors growth insulin-like normal growth Bag-1, as a new molecular marker of Bag-1, as a new molecular marker sensitivity in hormone- tamoxifen cancers breast responsive Program Highlights Program _ Refined and extended our models of and extended Refined _ Further defined mechanisms behind the _ how the activityCharacterised _ of Gab2, Sharad with Professor In collaboration _ _ Identified the anti-apoptotic protein, the anti-apoptotic Identified _ As well as basic research into cell and molecular biology, the Cancer Program has six translational research has six translational and molecular biology, Program the Cancer cell into As as basic research well cancers: breast, diagnosed and most lethal colorectal a number of the most commonly that study groups and prostate. lung,(bowel), ovarian, pancreatic Although derived from normal cells, cancer cells have distinctive features that can be exploited to aid diagnosis, to be exploited that can have distinctive cells features cancer normal cells, Although derived from that processes about the fundamental know much more need to do this, we To treatment, and prognosis. tissue behaviour: complex govern cell into their survival, their division, motility their and their differentiation of cancers. and early growth the formation stop able to will be better With this knowledge we structures. IIIIIIIII IIII Overview Program Dr Toby Hulf, postdoctoral researcher, using a Sequenom mass spectrometer to analyse the epigenetic profile of cancer cells.

_ Drs Alex Swarbrick and Sandra O'Toole, _ Rebecca Hinshelwood was awarded the in collaboration with Professor Neil Cancer Institute NSW 2008 Premier's Watkins at the Monash Institute of Award for Outstanding Research Scholar Medical Research, were awarded an _ Dr Sandra O'Toole, Dr Catriona McNeil NHMRC Project Grant to study Hedgehog and Haley Bennett were awarded PhDs signalling in breast cancer progression (University of NSW) _ Dr Matt Naylor was awarded research _ Chehani Alles was awarded a Master of grants from the Cancer Council NSW Science (University of NSW), Dr Ruban and the Prostate Cancer Foundation Thanigasalam a Master of Surgery Australia to investigate the role of (University of Sydney), Sarah Sutherland integrin signalling in prostate cancer and and Edwina Wing-Lun were awarded prostate development MBBS (Hons) (University of Sydney), _ Dr Pip O'Brien was awarded a priority- and Gabrielle Matta a BMedSci (Hons) People Highlights driven collaborative research grant from (University of NSW) Cancer Australia to investigate DNA _ Six senior investigators in the Cancer _ Professor Rob Sutherland completed a 3 methylation alterations as detection Research Program (Professor Roger Daly, year term as a member of the Scientific markers for early stage ovarian cancer Professor Liz Musgrove, Professor Rob Council of the International Agency for Sutherland, Associate Professor Chris _ Dr Alison Butt received a Research Cancer Research, Lyon, and a 5 year Ormandy, Professor James Kench and Innovation Grant from the Cancer term as a Board member of the Cancer Professor Andrew Biankin) were awarded Institute NSW to define novel molecular Institute NSW an NHMRC Program Grant worth determinants of anti-oestrogen _ Professor Susan Clark was appointed as $11,128,320 over five years to identify resistance in breast cancer and a the Australian representative on the molecular markers of phenotype, research grant from Breast Cancer Asian Epigenome Alliance, initiated and therapeutic responsiveness and Australia to further develop and evaluate appointed Convener of the Australian prognosis in human breast, prostate and the therapeutic potential of persin as an Epigenome Alliance, and continued as a pancreatic cancers anti-cancer agent member of the International Human _ Professors Roger Daly and Susan Clark _ Dr Alex Swarbrick, Associate Professor Epigenome Task Force were awarded renewals of their NHMRC Chris Ormandy, Professor Marie Dziadek, _ Cancer Program senior scientists are Principal Research Fellowships Professor Fabienne Mackay, Professor members of several major national and Sam Breit (St Vincent's Centre for _ Susan Clark and Liz Musgrove were international networks: Associate Immunology) and Professor Murray promoted to Conjoint Professor at the Professor Chris Ormandy in the Norris (Children's Cancer Institute University of NSW Australian Phenomics Network, Australia) were awarded a Cancer Associate Professor Sue Henshall and _ Dr Alex Swarbrick received Early Career Institute NSW Equipment grant to Professor Rob Sutherland in the Development Fellowships from the purchase an in vivo Imaging System for Australian and Canadian Prostate Cancer Cancer Institute NSW and the National live imaging of tumour growth and Research Alliance, Professor Susan Clark Breast Cancer Foundation metastasis in mouse models of cancer in the Alliance for Human Epigenetics _ Dr Matt Naylor received an NHMRC _ Professor Susan Clark was awarded a and Disease (AHEAD), and Dr Maija Career Development Award and an Early Cancer Institute NSW Equipment grant Kohonen-Corish in the International Career Development Fellowship from for purchase of a real-time cell analyser Human Variome Project the National Breast Cancer Foundation to dynamically monitor viability and proliferation of cancer cells in cell culture I I I I 20 CANCER PROGRAM IIII 21 CANCER PROGRAM Overall Conference Prize and Dr Ewan and Dr Prize Conference Overall given were Zardawi Millar and Sarah at the Australasian Commendations of Academy Division of the International Annual Scientific Meeting Pathology 33rd David Chang and Vivienna Ong were NSW Research Institute Cancer awarded was Locke Scholarships and Warwick Cancer National Breast a awarded Scholarship Research Foundation _ Dr Sandra O'Toole was awarded the awarded was O'Toole Dr Sandra _ Dr Simon Junankar, Shelley, Elizabeth _ Associate Professor Sue Henshall a Associate Professor Advisory member of the International and Breast the 4th PacRim for Group held in Meeting Cancer Prostate Canada in August Whistler, of the Elect Treasurer and Honorary Research, Medical Society for Australian of the 4th Australian Convener and was Congress Research Health and Medical held in Brisbane in November Inaugural with the WEHI Director's Award Lecture in Science Women Cancer in Pancreatic Award Hirshberg Pancreatic the American from Association in November meeting prizes received scientists postdoctoral presentations: poster their conference for Society for Brian Gloss at the Australian NSW Scientific Research Medical at the UNSW Meeting, Maria Gonzalez and Day, Faculty of Medicine Research Hulf at the 4th PacRim Dr Toby Cancer and Prostate on Breast Conference _ Dr Alison Butt was appointed President- appointed Butt was Dr Alison _ presented Clark was Susan Professor _ the Biankin received Andrew Professor _ and PhD students Program Cancer _ Program are members of 16 Editorial are Program On-Line, Cancer including Breast Boards, Journal British Research, Cancer Breast Cancer, Endocrine-Related of Cancer, Endocrinology, Epigenomics, Molecular Journal of Biotechnology and World Gastroenterology of the Gordon Vice-Chair appointed on Mammary Conference Research Gland Development in 2009, and Chair in 2010 of this conference members Chris Ormandy were Professor and Committee of the Organising Program served on grant review panels: served review grant on Program NHMRC, for Liz Musgrove Professor Chris Ormandy as Associate Professor Review Chair of the NHMRC CDA Marie Dziadek for Professor Committee, and the Health Awards NHMRC CDA NZ, Council Associate Research the Prostate Sue Henshall for Professor and of Australia, Foundation Cancer the Cancer Biankin for Andrew Professor NSW Council _ Senior staff members in the Cancer Senior staff _ Chris Ormandy was Associate Professor _ Sutherland and Associate Rob Professor _ _ Several members of the Cancer members of the Cancer Several _ Basic Cancer Research Cell Cycle Group Group Leader Professor Liz Musgrove Female steroid hormones like oestrogen and progesterone strongly influence cell reproduction in the breast. We are particularly interested in how these hormones act on the cell cycle machinery and how control over the cell cycle is lost in breast cancer cells. Our current work concentrates on the cell cycle genes c-Myc, cyclin D1 and cyclin E2, all of which are targeted by oestrogen and are overexpressed in breast cancer. In collaboration with the Steroid Hormone Action and Breast Cancer Translational Groups we are searching for new genes that might link oestrogen action with the cell cycle and so could be involved in resistance of certain breast cancers to the anti-oestrogen tamoxifen. We are collaborating with the Peter MacCallum Cancer Institute in Melbourne and the Diamantina Institute in Brisbane to undertake functional screens to identify genes involved in endocrine resistance. Steroid Hormone Action Group Group Leader Professor Rob Sutherland FAA Our research aims to determine and characterise the genes that mediate the actions of the sex steroid hormones oestrogen, progesterone, and androgens in steroid-responsive cancers (breast, prostate, ovarian and endometrial). These constitute a third of all newly diagnosed cancers. In collaboration with the Cell Cycle and Apoptosis Groups we have identified and are characterising a number of steroid-regulated genes involved in the control of cell proliferation, cell differentiation and cell death in breast cancer. In partnership with the Breast and Prostate Cancer Groups and the Cancer Development Laboratory we have demonstrated that some of these genes are new markers of cancer progression and response to therapy and candidate targets for the development of new cancer therapies. Apoptosis Research Group Group Leader Dr Alison Butt Oestrogen not only causes breast cancer cells to proliferate but it also protects them from apoptosis (cell death). We are investigating how this occurs and are identifying the genes that regulate this process. Such studies will enable us to understand how these genes may influence the way anti-oestrogens such as tamoxifen can effectively kill breast cancer cells. In other projects we are examining how novel compounds derived from plants induce apoptosis in breast cancer cells. This could lead to their development as new therapies for the treatment of breast cancer as well as other cancers. Signal Transduction Group Group Leader Professor Roger Daly Our research focuses on how signals regulating biological processes such as cell proliferation, survival and motility are transmitted within the cell, and how these signals are altered in cancer cells. We have determined that the activity of a key signalling I I I I 22 CANCER PROGRAM IIII 23 CANCER PROGRAM Professor Susan Clark Professor Chris Ormandy Associate Professor Swarbrick Dr Alex Dr Matthew Naylor protein, Gab2, is regulated by a class of binding proteins termed 14-3-3 that 'switch- 14-3-3 termed proteins of binding by a class is regulated Gab2, protein, identified have We cell. signals within the transmitting it from off' Gab2 and prevent that it is demonstrated and proliferation, as cell motility as well cell promotes that Gab2 development. we studies cancer other In of breast at very early stages highly expressed cell inside the mechanisms the regulatory regarding discoveries important have made for implications with factors, the action growth that modulate of insulin and insulin-like new have established we Finally, and growth. of animal metabolism the control phosphorylation associated in protein global alterations characterise to methodologies of novel the identification to applying these events, and are signalling with cellular treatment current to refractory in cancers markers and prognostic targets therapeutic cancers. such as basal-type breast regimens, Epigenetics Group Leader Group Cancer cells can modify the expression of critical cancer genes independently of the genes independently of cancer of critical modifycan cells Cancer the expression and DNA methylation called processes biochemical epigenetic using two DNA sequence, the mechanism that on understanding focuses research Our modification. histone normal and cancer between modification and histone triggers abnormal methylation early changes during methylation detect to methods have developed different We cells. place take changes can that these epigenetic development and have discovered cancer the of DNA during regions very large across also occur in single genes, but can only not diagnosis cancer for novel tumour "signatures" These changes provide of cancer. spread which determine now trying to are We therapy. cancer for targets as potential as well of events that and the sequence cancer and prostate breast specific to changes are and This is a large the process. reverse try can to trigger these changes so that we the on unravelling effort part international of the forms and our work project complex human epigenome. Group Development Leader Group governed by the that are stages in defined Development of the mammary gland occurs that genes controlling hypothesise events. We reproductive hormones that regulate cancer in breast or deregulated mutated normal mammary become development can that the transcription have discovered We the disease process. to and thus contribute the development of the mammary and also gland during pregnancy Elf5 controls factor investigating how are We cells. cancer and function of breast the proliferation regulates this mechanism. target therapeutically to a way provide these effects to Elf5 exerts Group Progression Tumour Leader Group endlessly (have they proliferate in common: features have two cancers aggressive Most are We cells. unspecialised, poorly differentiated mostly and contain high self renewal) a with in cancer, and differentiation self renewal investigating genes that control Group Translational Cancer with the Breast Together cancer. on breast particular focus of controllers key genes are that several have discovered we collaborators and external the These include cancers. of poorly differentiated (spread) and metastasis the growth and also the non-coding Id1, the Hedgehog signalling protein, regulator transcriptional progression cancer genes to of these the contribution Understanding microRNA-380. and may ultimately cancers metastatic the behaviour of aggressive will help us predict their growth. stop the development of new drugs to lead to BiologyCell and Group Integrin Leader Group decisions during fate cell the mechanisms that regulate understand aims to Our research the adhesion of cells mediate disease. Integrins metastatic to of cancer the progression with a positional identity in addition to cells matrix and provide the extracellular to function. cell Modulation control and hormone signalling to factor growth coordinating currently are phenotype. We cancer the and function alter can expression of integrin gland development and in functioninvestigating integrin during mammary and prostate also investigating the role are We and metastasis. models of carcinogenesis experimental during mammary gland development, regulators transcriptional fate cell of several and metastasis. cancer Translational Cancer Research Dr Warren Kaplan, bioinformatics specialist at Garvan's Peter Wills Breast Cancer Bioinformatics Centre, Group Leader Professor Rob Sutherland FAA discusses gene expression profiles (obtained from In association with clinicians at St Vincent's and other hospitals in Sydney we have microarray chips) with Dr Toby Hulf. developed large tissue banks and patient databases that are being used to identify markers of disease subtype, disease progression and response to particular therapies. A major joint project with the Cell Cycle and Steroid Hormone Action Groups is identifying molecular markers of tamoxifen resistance, since loss of response to tamoxifen is a major reason for treatment failure. We are also conducting collaborative studies in- house and with other institutions to define the role of newly-discovered breast cancer genes in the disease process. Lung and Colorectal Cancer Group Leader Dr Maija Kohonen-Corish Our area of expertise is colorectal and lung cancer genetics and epigenetics. We examine the gene profiles of resected tumour tissues and correlate them with patient clinical outcomes. The challenge is to work out which key gene alterations and biomarkers are the most useful for determining prognosis and treatment outcomes, in order to improve the clinical management of patients. We have identified new genes that are inactivated through epigenetic mechanisms in cancer. In lung cancer we have analysed genes on chromosome 3p, an area of the genome important in lung cancer development. We have shown that aberrant methylation may be synchronized in this region and that the presence of this defect in the cancer is associated with poor patient prognosis. I I I I 24 CANCER PROGRAM IIII 25 CANCER PROGRAM Professor Marie Dziadek Professor Dr Philippa O'Brien Sue Henshall Associate Professor Biankin Andrew Professor Research Director Research Cancer Therapeutics Development Laboratory Development Therapeutics Cancer for is investigating the potential Development Laboratory Therapeutics The Cancer cells. by cancer expressed molecular targets drugs against therapeutic developing cancer block the activity aims to project enzyme that is highly expressed of a key Our current the produce to cells This enzyme allows cancer types of cancer. in many different a high developed and completed We their growth. energy that is essential for with the WEHI/Bio21 HTS in collaboration library (HTS) of a chemical screen throughput that compounds inhibitor identified a number of potent in Melbourne. This screen facility will determine We growth. their efficacy cell in blocking cancer for will now be evaluated further drug development. lead for the best will form which of these compounds Ovarian Cancer Ovarian Leader Group Our group works in collaboration with the Gynaecological Cancer Centre at the Royal Centre Cancer with the Gynaecological works in collaboration Our group and expertise use our combined goal is to Our major research Women. for Hospital ovarian curable identify with early stage diagnose women knowledge to to new ways identify to the genes approaches utilise a number of different this end we To cancer. Our primary particularlyearly stages. its of ovarian cancer, involved in the development that have potential patterns methylation of genes with altered is the identification focus also aim to We ovarian cancer. early stage for markers as blood-based diagnostic development, ovarian cancer may which how such genes influence understand disease. with advanced women for additionally identify targets new treatment Cancer Prostate Leader Group therapeutic for of markers with the identification is concerned Our group take disease. We prostate of early and new markers markers, prognostic responsiveness, researchers a number of cancer from that utilises expertise a multidisciplinary approach identify aim to within and outside the Garvan, We and pathologists. as clinicians as well of the development predict changes can whose expression genes and pathways the used for chemotherapy to resistance or cancer prostate life-threatening aggressive cancer. prostate stage of advanced treatment Cancer Pancreatic Leader Group with a societies, death in Western is the fifth of cancer leading cause cancer Pancreatic and survival of less than 10%. The treatment of patients with five year survival rate has been little over thirty there years because changed for has not cancer pancreatic biology on with it. the molecular and cell associated into focus Our projects research decisions to guide therapeutic to patients by using biomarkers for outcomes improving molecular investigating are we In addition, cancer. pancreatic for personalise therapies the development of novel which may lead to carcinogenesis mechanisms of pancreatic strategies. therapeutic 2D gel showing proteins in mouse liver. IIII 27 DIABETES AND OBESITY PROGRAM entry into cells by activating cells entry a motor into known as myo1c, that helps protein, the cell to transporters move glucose surface signalling mechanisms behind insulin cell 2 Type for a risk factor resistance, the in particular reviewing diabetes, of a molecule known as importance be critical thought to IRS1, previously _ Showed that insulin regulates glucose that insulin regulates Showed _ the intricate novel insights into Reported _

compounds in bitter melon, a vegetable in bitter compounds helping Chinese medicine, and traditional treating for its potential us understand 2 diabetes Type of people with Type sensitive, relatives less of an appetite- secrete 2 diabetes meals than curbing gut hormone after in the family, those without diabetes gain weight to prone making them more in life later molecules, that may help inflammatory for being treated why people explain of diabetes have high rates HIV infection those who and heart disease, similar to very overweight and insulin resistant are _ Isolated four promising bioactive promising four Isolated _ that healthy weight,Found insulin- _ pro- mechanisms, involving Uncovered _

FAA Professor David James Professor

DIABETES & OBESITYDIABETES PROGRAM Leader fed a high fat diet by manipulating the by manipulating diet a high fat fed enzyme in metabolic levels of one key leg muscle 2 diabetes obese people with Type inflammation, which may be reduces insulin resistance important in reducing response known as ER stress (a known as ER stress response create ability to disruption of the cell's to a major contributor is not proteins) pancreatic the death of insulin-secreting it plays whereas 1 diabetes, in Type cells 2 diabetes in Type role a significant _ Improved insulin resistance of rodents insulin resistance Improved _ in morbidly reduction that weight _ Showed _ Demonstrated that the cellular stress that the cellular Demonstrated _ Program Highlights Program Our basic and clinical research efforts are closely linked. We ask ourselves the major questions about why ask ourselves We linked. closely are efforts research Our basic and clinical and genetic, including dietary might be involved. Many of our factors, develops and what other diabetes very identify early in that occur to in an effort factors diabetes risk for on humans with a genetic focus studies immune from identify that may be released of the disease. Such studies have begun to the onset factors blood parts of the body. different from in fat differences key examining or blood vessels and are cells The growing incidence of obesity is driving a worldwide epidemic in Type 2 diabetes, a disease which already diabetes, 2 of obesity is driving a worldwide epidemic in Type incidence The growing on the molecular is focused in this program population. Research affects nearly 1 in 10 of the Australian at 2 diabetes of Type understanding a better and obtaining metabolism, and fuel of body weight regulation of insulin and its mode of action in normal and on the release a particular is emphasis both multiple levels. There the discovery for the use of mass spectrometry microscopy, cell include live strengths Research disease states. studies in humans. in vivo gene manipulation and metabolic disease, by metabolic of new molecules affected IIIIIIIII IIII Overview Program People Highlights Research Groups _ The Diabetes and Obesity Program was Appetite and Adiposity in Pre-diabetes and Prader Willi Syndrome awarded an NHMRC program grant Group Leader Professor Lesley Campbell AM worth $10.5 million over 5 years Our group studies the basic abnormalities in metabolism in people with disorders of _ Professor David James was invited to prediabetes and obesity. One major focus is the study of a genetic disorder that occurs give the 2008 Novo Nordisk frequently in young children, known as Prader Willi Syndrome (PWS). This disorder is International Lectureship at the commonly associated with lower lean body mass, and with relentless childhood weight University of Toronto gain, and so is of great interest in our understanding of the genetics of human body composition. These studies, in collaboration with Royal Prince Alfred Hospital and _ Dr Kyle Hoehn was awarded the 2009 Professor Herbert Herzog's laboratory (Garvan Neuroscience), compare hormonal and Viertel Fellowship from the Diabetes metabolic differences to matched obese subjects as well as testing potential therapeutic Australia Research Trust (DART) options. Studies are underway to prepare a novel mouse model of PWS based on a very _ Dr Jiming Ye, Dr Bronwyn Hegarty, recent genetic discovery about the nature of PWS genes. A second major focus of our Professor David James, Dr Jerry group is identification of the factors that predispose individuals to Type 2 diabetes. Greenfield, Dr Carsten Schmitz-Peiffer These studies have revealed a predisposition to eat more (low levels of PYY hormone), and Associate Professor Trevor Biden an increased innate immune and T cell activation (better at fighting primitive organisms were awarded NHMRC project grants but more tendency to inflammation and possibly atheroma) and a more active "fight and flight" response (but also more central fat, more hypertension and metabolic syndrome). _ Dr Katy Raddatz was awarded a German Research Foundation (DFG) Post- Fat and Insulin Resistance Doctoral Fellowship Group Leader Professor Don Chisholm AO _ Amanda Preston and James Burchfield We have been studying patients with hepatitis C because of their predisposition to successfully obtained their PhD degrees insulin resistance and Type 2 diabetes. We have shown that the insulin resistance is present in muscle rather than in liver, contrary to common belief. We have also identified _ Associate Professor Katherine Samaras for the first time an elevation in glucagon in these patients, which may also contribute was invited to participate in the to Type 2 diabetes. The group continues their work on abdominal obesity and, in Australian Academy of Science's Theo collaboration with the Cell Biology group, is undertaking studies of adipose tissue Murphy High Flyers Think Tank and also transplantation in mice. the National Preventive Healthcare Summit for the National Preventative Molecular Metabolism Health Taskforce, “Curbing the Obesity Group Leader Associate Professor Greg Cooney Epidemic: the role of the individual and Fat accumulation causes problems with metabolism that can lead to Type 2 diabetes, the role of the State” heart disease and stroke. The major focus of the Cooney group is to understand factors _ Professor Lesley Campbell was an invited (genetic and environmental) that control fat accumulation in muscle and liver and to use plenary speaker at the IASO Stock this information to devise strategies to reduce fat. When fat enters a cell from blood Conference in March 2008 on "Hormones there are two major choices for its fate. It is either stored as an intracellular lipid or it is and Obesity"; as well as at an International channelled into the mitochondria, where it is burned for energy. We are studying the Symposium on Obesity at the Institute regulation of glucose and fatty acid metabolism by mitochondria and the changes that of Preventative Medicine in Copenhagen. occur in normal metabolic cycles when tissues are exposed to too much fat at different times of the day. This could help explain the contribution of increased food availability _ Dr Alex Viardot was awarded the inaugural and altered eating habits to the rapid increase in obesity and metabolic disease. Don Chisholm Fellowship for 2009 I I I I 28 DIABETES AND OBESITY PROGRAM 2D gel. IIII 29 of particular proteins Islet Biology Group, and BiologyIslet Group, postdoctoral researcher researcher postdoctoral (molecules), as shown on a Dr Ross Laybutt, head of the Dr Katy Raddatz levels discuss DIABETES AND OBESITY PROGRAM Associate Professor Antony Cooper Antony Associate Professor Dr Jerry Greenfield ER Stress and Protein Misfolding and Protein ER Stress Leader Group Our group aims to understand how cells cope, or fail to cope, with the stress that can with the stress cope, to or fail cope, how cells understand aims to Our group within a cellular of proteins and misfolding of proteins the over-production from result a to applicable is directly (ER). ER stress the endoplasmic reticulum called compartment like as many diseases of the brain as well number of diseases including diabetes, growing 'burns disease. Either the cell neuron and motor Alzheimer's Parkinson's, Huntington's, unmanageable amounts or accumulates of harmful products, an excess out', generates by which death. If the mechanism cell lead to ultimately which of unusable proteins, of this may enable identification be elucidated, death can cell induce these stressors demands. deal with extra help cells points of intervention to potential Human Physiology Leader Group to a major study undertaking are we Biology with the Cell group, In collaboration at-risk individuals. muscle from identify in skeletal in insulin signal transduction defects nervous of the autonomic in the system the possible role also examining are We the examining have also been established Studies and obesity. development of diabetes in isolation and in combination both an amino acid, on metabolism, effects of glutamine, effect on have a promising appears to Glutamine medication. with a new diabetes a simple, novel and effective and may offer state in the post-meal lowering glucose 2 diabetes. in Type treatment Phospholipid Biology Group Leader Dr Will Hughes Phospholipids are the basic building blocks of cell membranes but, as is becoming clearer, some are also dynamically regulated to enable control of many of the major functions of cells. Two such examples are the stimulated secretion of insulin from pancreatic beta cells after a meal, and the movement of glucose transporter GLUT4 to the plasma membrane in muscle cells to allow glucose uptake in response to insulin. We continue to use state-of-the-art live cell microscopy to see where and when in individual cells the dynamic changes in phospholipids occur to determine how they may regulate insulin release or GLUT4 movement. In collaboration with the Cell Biology and Molecular Metabolism groups, we aim to identify precisely which intracellular processes may be defective in diabetes. Cell Biology Group Leader Professor David James FAA A major action of insulin that becomes defective in Type 2 diabetes is the regulated entry of nutrients into muscle and fat cells. The goal of our group is to use newly developed molecular imaging methods to study the insulin-regulated movement of the GLUT4 glucose transporter as well as other processes in insulin responsive cell types. Also using mass spectrometry, novel molecules involved in insulin action have been identified and these represent the focus of many future studies. These studies dovetail with a major investigation into the mechanism of insulin resistance in muscle and fat, with recent studies from the group highlighting an important role for oxidative stress. Diabetes and Metabolism Group Leader Professor Edward Kraegen Understanding how too much fat causes insulin resistance in muscle and liver is the major thrust of our work. Various experimental models and state-of-the-art techniques are being used to identify and manipulate key proteins in muscle that link fat metabolism to insulin action. Important pathways under investigation are those activated by the newly discovered hormone adiponectin and involving the enzyme AMP-kinase. Studies using traditional Chinese medicines with collaborators in Shanghai to identify new insulin-sensitising agents that could be more useful than current therapeutics are also underway. Excitingly, some of these molecules modulate AMP-kinase, a major intracellular regulator of cellular energy status. Work is also ongoing in partnership with pharmaceutical companies to identify ways of reducing fat accumulation by influencing the rate of entry of fatty acids into mitochondria for oxidation. Obesity in Diabetes and Diabetes and HIV Group Leader Professor Katherine Samaras Obesity is the major accelerating factor in the pathogenesis of Type 2 diabetes in humans. We have been studying the progress of obese diabetic patients in response to weight loss regimens, finding 60% will normalise glucose tolerance within 12 weeks after bariatric surgery. Early results show these rapid improvements in diabetes are not explained by weight loss, but associated with immune system changes. This work continues to dissect the role of circulatory and tissue-based inflammation in response to weight change, thus providing valuable insights into pathogenesis and potential therapeutic targets for treating the commonest form of diabetes. Work in people living with HIV infection, in collaboration with St Vincent's Hospital and the National Centre for HIV Epidemiology and Clinical Research, showed treatment-induced metabolic syndrome, predicting subsequent premature development of Type 2 diabetes and heart disease. Studies of how these drugs affect glucose and lipid metabolism and vascular function are now underway. In particular, patients are being followed over a 10 year period, in one of the longest longitudinal cohorts internationally. I I I I 30 DIABETES AND OBESITY PROGRAM IIII 31 DIABETES AND OBESITY PROGRAM Associate Professor Trevor Biden Trevor Associate Professor Dr Ross Laybutt Schmitz-Peiffer Dr Carsten Beta Cell Signalling Cell Beta Leader Group cell acids disrupt beta fatty mechanisms whereby Identifying the cellular and preventing the progression to fundamental are function is one of our major goals. These processes the mechanism piecing together are We poorly understood. are yet 2 diabetes, of Type be a key to an enzyme they found kinase C epsilon (PKCe), of action of protein identify underway of to inhibitors are Studies insulin secretion. of defective determinant is major project Another 2 diabetes. Type for therapy this enzyme as a possible future death, with particular cell acids and beta fatty the molecular links between examining have we biology in the Islet with colleagues group, notably, Most emphasis on ER stress. of human subjects cells in beta occurs time that ER stress the first shown for recently 2 diabetes. with Type Islet Biology Leader Group Our goal is the development of diabetes. to is fundamental failure beta-cell Pancreatic destruction and the loss of insulin the beta-cell identify for to responsible mechanisms 2 under investigation is that in Type The major hypothesis diabetes. that cause secretion a loss and lipid levels leads to (hyperglycaemia) rise in blood glucose a gradual diabetes insulin secretion. appropriate for of genes necessary pattern of the unique expression and dedifferentiation further which causes beta-cell hyperglycaemia, This worsens of the role investigations into 1 diabetes, death. In models of Type eventually beta-cell destruction beta-cell for as a mechanism responsible (ER) stress endoplasmic reticulum as ER stress for a role against argues our group from work Recent being conducted. are the situation in to in contrast 1 diabetes, destruction in Type beta-cell a mechanism for 2 diabetes. Type Insulin Signalling Leader Group that disrupt insulin signaling and how these contribute on the lipid metabolites focus We that di- by the discovery has been initiated area A new study resistance. insulin to In collaboration of insulin signaling. inhibitor linoleoyl phosphatidic acid is an important in progress are of this metabolite with industry block production partners, to studies is kinase C epsilon of our group in human subjects. focus by verification Another followed whole-body availability of insulin. This, action decrease which exerts on liver to (PKCe), as inhibiting PKCe, for reason a second constitutes its actions cells, in addition to in beta is being used approach In addition, a proteomics 2 diabetes. Type for therapy a potential which blocking of the lipid-activated inhibitory through the mechanisms understand to tissues. in insulin target metabolism glucose improves molecule PKCe Diabetes Signalling Unit Signalling Diabetes Decanting medium off adherent spleen cells. IIII 33 IMMUNOLOGY AND INFLAMMATION PROGRAM AND INFLAMMATION IMMUNOLOGY asthma, developed a therapeutic antibody against GM-CSF development IgE is of IgE by B cells. production many of the symptoms for responsible a novel This represented of allergy. IgE production of the way understanding is regulated a key of IL-21, features and structural molecule of the immune regulatory with the aim of developing new system, and cancers certain treat drugs to diseases autoimmune can CD4+ T cells immunoregulatory of acceptance long-term induce without allografts islet pancreatic immunosuppression _ In collaboration with the CRC for In collaboration _ heart Identified CXCR7_ as a gene for of the as an inducer Identified IL-21 _ the basic biochemistry Characterised _ levels of that raised Demonstrated _

certain class of immune cell), which play class of immune cell), certain of in triggering the production role a key antibodies, need the molecule IL-21 survive function to to and both a key of IL-21, features structural molecule of the immune regulatory with the aim of developing new system, and cancers certain treat drugs to diseases autoimmune a gene that behind the action of Stat3, help typesworks to in all immune cell at bay and bacterial fungal infections keep block C5aR - developed to antibody we in inflammatory a molecule implicated arthritis, such as rheumatoid conditions diseases, eye diseases autoimmune and sepsis which has many different GM-CSF, actions in various immune and plays an responses, inflammatory in asthmatic airway important role inflammation Program Highlights Program _ Showed that T follicular helper cells (a helper cells T follicular that Showed _ Identified the basic biochemistry and _ the molecular mechanisms Elucidated _ of an began in Europe Human trials _ that the cytokine in mice Established _ Program Overview Program study aspects immune function of in normal and Our researchers diseases such the basis for understand hope to diseased situations. We and asthma, and diseases, diabetes arthritis, autoimmune as rheumatoid with also collaborate disease. We treat to develop new therapies also to such as projects on cross-discipline Garvan programs in other scientists and immunology cancer systems, finding links between and metabolic the nervous system. FAA Professor Charles Mackay Professor

IMMUNOLOGY & INFLAMMATION PROGRAM & INFLAMMATION IMMUNOLOGY Leader IIIIIIIII IIII People Highlights _ Sandra Gardam was invited to present _ Kendle Maslowski received an NH&MRC _ Helen McGuire received the following at the annual scientific meeting of the PhD Scholarship and received the awards: St Vincents & Mater Health Russian Society of Immunology held in following awards: Transplant Society of Research Symposium Award for Excellence St Petersburg. Sandra was awarded an Australia and New Zealand (TSANZ) in Oral Presentation; ASI travel bursary NHMRC Training Fellowship - Overseas Travel Grant; Best Presentation Award, to FIMSA Taiwan conference; and Castle Based Biomedical Fellowship TSANZ ASM (for best oral presentation Harlan Award - most outstanding early in the Cell Biology SIG); Australian career PhD student _ Alexis Vogelzang was awarded New Society for Immunology travel grant. Investigator of the Year at the annual _ Professor Jonathan Sprent gave invited He gave Oral presentations at the 2nd scientific meeting of the Australasian presentations in Davos and Lausanne in World Immune Regulation Meeting, Society of Immunology held in Canberra Switzerland, Florence in Italy, Tokyo and Davos Switzerland; the Thoracic Society Tokushima in Japan, and Havana in Cuba _ Dr Daniel Christ was an invited speaker of Australia and New Zealand Annual as well as meetings in Melbourne, at the following meetings: the annual Scientific Meeting in Melbourne; and the Brisbane and Canberra Protein Engineering Summit (Boston), Australian Society for Medical Research, CBSM (Perth) and at research N.S.W. branch _ Dr Di Yu was invited to the following institutions and companies (Monash, conferences: The 10th International _ Stacey Walters received a Novartis CSL). He was awarded a CDA Fellowship Workshop on Auto-antibodies and Young Investigator Travel Award; from the National Health and Medical Autoimmunity, Mexico and the American Transplant Society of Australia and New Research Council (NHMRC) College of Rheumatology Annual Zealand (TSANZ) New Key Opinion Scientific Meeting, San Francisco, The _ Kip Dudgeon received a postgraduate Leader Best Abstract Award; TSANZ United States. He was also awarded a scholarship from the NHMRC President's Prize Award; and St. Vincent's C.J. Martin Fellowship Symposium Poster Prize _ Dr Tri Phan, NHMRC CJ Martin Fellow _ Dr Jenny Gunton was an invited speaker from UCSF, returned to Garvan in Dr _ Stacey Walters, Rebecca Stokes, Kylie at the Endocrine Society of Australia/ Rob Brink's laboratory. Tri was previously Webster and David Liuwantara received Australian Academy of Science rising star working with Dr Jason Cyster on 2 a Transplant Society of Australia and symposium; an invited speaker at the Photon Microscopy New Zealand Young Investigator Award Endocrine Society of Australia Clinical _ Kylie Webster won a St Vincent's _ Alexis Vogelzang, Helen McGuire and Symposium weekend, is honorary Research Symposium Award for Oral Santi Suriyani received an ASI Travel Award secretary of the Australian Diabetes Presentation and a TSANZ (Transplant as well as FIMSA travel bursary to Taiwan Society and is the chair of the program Society of Australia and New Zealand) organising committee for the ADS annual _ Dr Sue Mei Lau received the Novartis Young Investigator Award scientific meeting. She was awarded a Junior Scientist Prize at the Endocrine JDRF ITP research grant and a a Diabetes _ Emeritus Professor Antony Basten was Society of Australia Annual Meeting and Australia Research Trust grant an invited speaker at the following a Diabetes Australia Research Trust grant. meetings: The Kunkel Society annual _ Professor William Sewell was an invited _ David Liuwantara received a Merck meeting on autoimmunity (Santa speaker at the Australian Dermatology Company Foundation Fellowship Margherita, Italy), International B cell Update Symposium in Sydney and the Workshop on vaccination (Oxford, UK) _ Dr Cecile King was invited speaker at Frontiers in Otorhinolaryngology and the 12th Australasian Autoimmunity the Australasian Diabetes Society Annual Conference in Noosa Workshop( Sydney) Meeting. CK received an Innovative _ Dr Sue Lynn Lau won the dance your grant from the Juvenile Diabetes _ Dr Stuart Tangye was invited to present PhD competition, and was awarded a a Research Foundation and an NHMRC seminars at conferences held in New Diabetes Australia Research Trust grant project grant Zealand, Brisbane, New York, and at research institutes in Bethesda (NIH), Melbourne (WEHI), New York (Rockefeller University), and California (DNAX Research Institute) I I I I 34 IMMUNOLOGY AND INFLAMMATION PROGRAM IIII 35 nodes and spleen. production in the lymph production with PhD student Helen The MACS uses magnetic The MACS Mucosal Immunity Group, Mucosal McGuire using a Magnetic McGuire Dr Cecile King,Dr Cecile head of the on cells of interest - in this of interest on cells cells) which direct antibody direct which cells) of T cells (T helper of T cells follicular beads coated with antibody beads coated case purifyingcase (white T cells to bind to surface molecules surface bind to to Dr King's lab studies a subset blood cells) from spleen cells. spleen cells. from blood cells) Activated Cell Sorter (MACS). Sorter Activated Cell IMMUNOLOGY AND INFLAMMATION PROGRAM AND INFLAMMATION IMMUNOLOGY FAA Dr David Zahra* Professor Charles Mackay Professor Our group focuses on the development of a promising therapeutic that neutralises the that neutralises therapeutic on the development of a promising focuses Our group a number of to GM-CSF has been linked function of the cytokine GM-CSF. have arthritis, and we and rheumatoid diseases including asthma inflammatory been successfully This antibody has developed an antibody that blocks GM-CSF. that our antibody binds on GM-CSF has been defined. The 'humanised' and the epitope pre- for and is now ready patents provisional by two is protected therapeutic potential with in collaboration is being conducted study A feasibility studies. and toxicology clinical pre- for the therapeutic with the aim of fully licensing company a major pharmaceutical development by the end of 2009. clinical and clinical *Part of the CRC for Asthma and Airways of the CRC for *Part Immunology lies at the heart of many human diseases. Poor immune responses can lead can Immunology immune responses lies at the heart of many human diseases. Poor lead to immune responses Over-zealous or infections. the development of cancers to arthritis and rheumatoid 1 diabetes, diseases such as Type or autoimmune allergies, and molecular processes all of the cellular understand trying to are We multiple sclerosis. are we disease. Increasingly, cause to goes wrong and what of immune responses, and the metabolic the immune system connections between integral discovering has activity One important of our program the nervoussystem, and cancer. system that will impact on the health of new treatments into discoveries translate been to intervene development of antibodies that can in the have led to mankind. Our studies by Garvan being developed and these are spin-off G2 Therapies process inflammatory and and asthma; diet, acid binding proteins the link between fatty studying are We Ltd. diseases because and metabolic inflammatory at the links between broadly looking more affect various aspects that can of factors release cells now know that inflammatory we and our diet, that gut microbes, a new hypothesis also exploring are We metabolism. responses. of inflammatory the nature determine Asthma Leader Group Immunology and Inflammation Leader Group Research Groups Research Cellular Immunity Group Leader Professor Jonathan Sprent FRS FAA Our team is interested in the development and fate of T cells - white blood cells that participate in a variety of immune responses but are able to somehow distinguish between self and foreign antigens. One of the unknown questions that is central to maintaining the immune system's homeostasis is how are these cells destroyed once their mission is complete and infections are overcome? We know that most self- destruct and a few live on to become memory T cells, which are activated by a re- infection, but we don't know the factors that determine their destiny. Application of our work lies in harnessing the immune system to boost its attack on cancerous tumours and, conversely, dampening down the immune response to treat autoimmune diseases. Diabetes and Transcription Factors Group Leader Dr Jenny Gunton The causes of beta-cell failure are not well understood, but we know there are changes in these cells' gene expression that can yield clues about what is going wrong. Through the use of a variety of tissue-specific knockout and transgenic mice we hope to identify why beta cell failure occurs as well as ways to improve beta cell function and thereby treat human diabetes. We are currently focusing on a gene called ARNT, which is decreased by 90% in the beta cell containing islets of people with Type 2 diabetes. It seems to be a master gene that controls other genes involved in beta-cell function, including glucose breakdown and insulin production. We are now looking at ways to control ARNT. Gene Therapy & Autoimmunity Group Leader Dr Shane Grey Our laboratory is interested in the how and why of the immune system's attack on the body's tissues as it occurs during the rejection of organ grafts and in autoimmune disorders like Type 1 diabetes where the insulin-producing beta cells are destroyed. Approaches include examining factors that regulate the immune attack on our own cells and investigating the molecular changes that occur in the tissue being attacked in the hope of, one day, being able to genetically engineer tissues that could withstand the assault. This strategy would alleviate the need for the toxic immunosuppressive drugs currently required to promote successful organ transplantation and, in the case of Type 1 diabetes, enable creation of a 'death-defying' beta cell as a novel cure. Immunobiology Group Leader Dr Stuart Tangye Our focus is on understanding the development of B cells - the population of white blood cells responsible for the production of protective antibodies - and the regulation of antibody responses. We are particularly interested in understanding how the immune system responds to infections or vaccinations by providing us with a 'memory' of the response so that we cope faster and better with subsequent exposure from the same infectious agent. The development of immunological memory involves interactions between B cells and 'helper' T cells - another subset of immune cells. Thus, a major focus of our work is to understand exactly how helper T cells instruct B cells to produce antibodies. We also study several genetic conditions of the immune system, and corresponding mouse models, that result in immunodeficiencies - disorders whereby affected individuals are unable to mount appropriate immune responses following exposure to some infections or pathogens. These diseases include X-linked lymphoproliferative disease, common variable immunodeficiency and hyper-IgE syndrome. Overall, we hope to identify means to improve the immune response in individuals with immunodeficiencies and, conversely, ways in which the immune system of patients with autoimmune diseases could be attenuated. I I I I 36 IMMUNOLOGY AND INFLAMMATION PROGRAM IIII 37 IMMUNOLOGY AND INFLAMMATION PROGRAM AND INFLAMMATION IMMUNOLOGY Dr Cecile King Dr Cecile Dr Daniel Christ Mucosal Autoimmunity Mucosal Leader Group In Type 1 diabetes, the insulin-producing beta cells of the pancreas are destroyed by destroyed are of the pancreas cells beta the insulin-producing 1 diabetes, In Type determine, that help us to markers express self tissue-destructive These cells T cells. they have been in the and where factors upon growth their dependence example, for that cause the cells between in the relationship particularly interested are We body. interface diseases that develop at the mucosal autoimmune and other 1 diabetes Type is immunosuppression bodies and the environment. our Broad-based between but it has an recipients and transplant diseases autoimmune treat used to commonly thrive. The to need a functioning we in order immune system since obvious drawback of these selective suppression molecules for identify is to target aim of our research cells. self-tissue-destructive Antibody Engineering Leader Group In antibody therapeutics. on the development of novel is working Our laboratory which in the engineering of human antibody fragments, interested are we particular, antibody monoclonal antibodies. Human smaller than current considerably are engineering by genetic be generated (such as domain antibodies) can fragments be can bypassing the use of animals. These fragments completely technology, non- for new routes quantities in bacteria and open up promising in large produced applying our technology to are We therapy. imaging and applications, intravenous diseases. and inflammatory in cancer targets Spinal X-ray with fractures. I I I I I I I I I OSTEOPOROSIS & BONE BIOLOGY PROGRAM I I I I Leader Professor John A Eisman AO

Program Overview Osteoporosis affects older men and women. It brings with it major costs to the individual and community, serious impacts on being able to live productively and also premature mortality. As prevention is the best strategy for reducing this large human and financial burden, we need to improve our knowledge of the risk factors from fracture; find ways to better assess treatments; increase our understanding of bone biology; and help identify new treatment possibilities.

Program Highlights _ Data from the Dubbo Osteoporosis _ Participated in the first multi-nation Epidemiology Study demonstrated the genome-wide search to find genes association between fragility fracture linked to osteoporosis and fracture, and premature mortality in both men resulting in the identification of several and women for all types of osteoporotic chromosomal regions that could harbour fractures novel osteoporosis-risk genes _ Developed prognostic models for _ Showed, by combining our own study predicting an individual's fracture risk with studies by other research groups, and incorporated them into a web-based that individuals with specific variants of calculator, at a major bone regulating gene are at www.fractureriskcalculator.com, used by increased risk of reduced bone mass and doctors and patients worldwide fracture, information which can be included in fracture risk calculation _ Collaborated with several major international and national research teams _ Demonstrated, through a study on more all seeking to validate and use our risk than 600 men, that those with levels of calculator in their data testosterone below specific levels are at greater risk of fracture _ Demonstrated the central (brain) control of bone cell function, the relief (or _ Demonstrated that men with prostate reduction) of which leads to a doubling cancer, particularly those who received of bone volume androgen deprivation therapy, had an increased fracture risk _ Further characterised the neural signalling pathway in bone that allows _ Used a Bayesian (statistical) method to the brain to control bone mass and estimate the probability of sport doping; strength (a collaborative project with the based on certain blood hormone levels Garvan Neuroscience Program) (a collaborative study with colleagues from Garvan's Pituitary Research Unit) I I I OSTEOPOROSIS AND BONE BIOLOGY PROGRAM 39 I People Highlights _ Professor John Eisman chaired the Montreal, Canada. She was also development group for Guidelines for awarded a Novo Nordisk clinical grant Osteoporosis Management supported by examining effects of vitamin D the Federal Department of Health _ Dr Paul Baldock was invited to join a through the Royal Australian College of review panel for NHMRC Project Grants, General Practitioners. He was invited as and to present to the Kings Cross Rotary a key opinion leader to the Department Club, following from their Excellence in of Health and Ageing funded Quality Use Workmanship Award. He was awarded a of Medicines (QUM) in Osteoporosis, travel grant from the International Bone Osteoarthritis and Rheumatoid Arthritis and Mineral Society to present at the (QUM OPORA) Workshops in Sydney exclusive Davos Workshop: Bone (November 2007). He is chair of the Biology & Therapeutics in Switzerland; Local Organising Committee for the invited to present at a Symposium to International Bone and Mineral Society the Australasian Paediatric to meet in Sydney in 2009 Endocrinologist Group (APEG) Annual _ Professor Tuan Nguyen was promoted to Meeting in Broome and to give a full Professor at the University of New Symposium Presentation at the 2008 South Wales and was awarded a Senior European Society for Clinical Research Fellowship by the National Investigation. He has been invited to Health and Medical Research Council. He present in the opening symposium at successfully convened the international the 2009 annual conference of the osteoporosis meeting Strong Bone Asia American Society of Bone and Mineral in Ho Chi Minh City, Vietnam, which Research in Denver Colorado attracted 500 participants from Asia _ Osteoporosis and Bone Biology program and Pacific region. He was also invited to students successes include: Steve Frost present his work in 3 symposia on given best presentation award, UNSW osteoporosis in Hanoi, Ho Chi Minh City, Student Conference; Bich Tran awarded and Can Tho (Vietnam), and with Dr a Solander Program scholarship for Nguyen Nguyen was invited to conduct collaborative work with Lund University, a workshop in epidemiological methods Sweden and a Harvey Carey Memorial in Hanoi. He also presented his work on Trust Scholarship; Ayse Zengin awarded the individualisation of fracture risk at an APA Scholarship; Iris Wong and Bich the 13th National Health Outcomes Tran awarded travel grants to attend the Conference in Canberra Australian and New Zealand Bone and _ Dr Jackie Center was promoted to Mineral Society Meeting, Melbourne Associate Professor (Conjoint) at the and Bich Tran a UNSW travelling grant University of New South Wales. She has to attend the ASBMR Scientific Meeting pioneered the Dubbo study's work on in Montréal premature mortality after osteoporotic _ Dr Nina Emaus from Norway joined the fractures in men and women. This work Epidemiology group for six months and gained two prestigious oral presentations Dr Frank Driessler from Berlin joined the at the recent American Society for Bone Baldock Group and Mineral Research meeting in I I I I 40 OSTEOPOROSIS AND BONE BIOLOGY PROGRAM IIII 41 OSTEOPOROSIS AND BONE BIOLOGY PROGRAM AND BONE BIOLOGY OSTEOPOROSIS AO Professor Tuan Nguyen and Associate Professor Jackie Center Center Jackie Nguyen and Associate Professor Tuan Professor Dr Paul Baldock Dr Paul John Eisman Professor Our clinical studies group continues to participate in multicentre international clinical international in multicentre participate to continues group studies Our clinical of in the final stages that are treatments osteoporosis trials evaluating potential at remain development. we pharmaceutical helps ensure Involvement in these studies to an entry pathway and provides the cutting edge of knowledge of novel therapies novel developments. in our interest pharmaceutical The hallmark of osteoporosis is a reduction in bone density and therefore strength. It is strength. in bone density is a reduction and therefore The hallmark of osteoporosis is, primarily, and bone loss. Our group bone formation between by an imbalance caused and strength. bone formation hormones, which influence of brain investigating the role out in mouse models and is carried use of transgenic makes Much of this work The effect this pathway of Program. in the Neuroscience with researchers collaboration to a major approach and this suggests reported than any previously on bone is larger new treatment. Studies - Clinical Prevention Fracture Leader Group Research Groups Research Risk Fracture of Osteoporotic Individual and Genetic Determinants Population, and their Outcomes Leaders Group Epidemiology (DOES) began in 1989 and is the world's Study The Dubbo Osteoporosis in men and fractures of osteoporotic study epidemiological running large-scale longest models, based on multiple develop predictive to DOES data using the are women. We who determine and to identify to at high risk of fracture men and women risk factors, search to also continuing are interventions. We preventative from would benefit most at low risk of osteoporosis those who are genes that may predict new osteoporosis for such as physical activity, factors falls- environmental account into - taking and fractures how Finding and understanding and hormonal factors. nutrition, medication related, affect bone biology factors with each and genetic how they and interact factors clinical as identify as well therapies will help identify optimal use of existing other individuals for novel therapies. for targets Bone Regulation Leader Group Associate Professor head Center, Jacqueline and of the Bone Clinical Epidemiology Research advises a patient Group, low for on treatment bone density. Mouse olfactory neuroepithelial sections prepared for adult stem cell analysis. IIII 43 NEUROSCIENCE PROGRAM cells, an abundant and accessible source an abundant and accessible cells, the inner into transplanted cells, of stem noise-induced improved ear of mice, hearing loss show the brain in neurons processing and levels of excitation different hear inhibition, which affects how we sounds in a noisy room cell activin-A stem stimulates the neural to and repair proliferation disease, damage in Parkinson's which injury, Alzheimer's and spinal cord implications has important therapeutic _ Showed that adult mouse tongue stem that adult mouse tongue Showed _ sound that different Identified _ that a hormone called Demonstrated _

Neuropeptide Y and its receptor are Y and its receptor Neuropeptide of olfactory the proliferation for critical so by blocking Y1 receptors cells, stem it may be possible to therapeutically, into differentiate to cells stem stimulate new tissue when required high levels of produce to engineered a hormone that subdues appetite PYY, against protected a meal, were after obesity and genetic diet-induced of PYY a higher risk of developing have 2 diabetes Type Y and sex Neuropeptide between and testosterone), (oestrogen steroids bone turn regulate in which both and body fat strength Program Overview Program our understanding increase aims to Program Research The Neuroscience neurodegenerative Disorders, involved in Eating systems of the neuronal as disease and Alzheimer's disease as well such as Parkinson's disorders these for identify approaches aim to new therapeutic hearing loss. We of the nervous for system in regeneration diseases with a special interest A key cells. purposes with a specific emphasis on adult stem therapeutic of energy control of the brain's understanding is also the better focus which affects and expenditure), (balancing energy intake homeostasis gain. and weight mood, fertility, Program Highlights Program chemical that a brain Discovered _ genetically that mice Demonstrated _ low levels that people with Discovered _ interplay a critical Demonstrated _ Professor Herbert Herzog Herbert Herzog Professor

NEUROSCIENCE PROGRAMNEUROSCIENCE Leader IIIIIIIII IIII People Highlights _ Professor Herbert Herzog was an invited speaker at the 9th International NPY Congress in Okinawa, Japan. He was also a presenter at the Keystone Symposia on Obesity, Fairmont Banff Springs, Alberta, Canada _ Dr Amanda Sainsbury-Salis was promoted to Associate Professor. She was an invited Conference Chair and speaker at the International Association for the Study of Obesity (IASO) Stock Conference 2008 on Gender Aspects of Obesity, Bangkok, Thailand. She was also invited to present at the Australian Health and Medical Research Congress in Brisbane _ Dr Sharon Oleskevich was an invited speaker at the international Adult Stem Cell-Biology and Clinical Applications Conference, Griffith University, Brisbane, and at the International College of Geriatric Psychoneuropharmacology at the University of NSW, Sydney _ Andrea Abdipranoto and James Daniel received their PhDs and Sandy Stayte completed her honors year _ Dr Bryce Vissel was a keynote speaker at the National Parkinson's Conference and is a founding member of the Australian and New Zealand Spinal Cord Injury Network

Dr Kharen Doyle, post- doctoral researcher, uses a 'microtome' to slice wax- embedded tissue samples. Kharen investigates the potential of adult neural stem cells for treatment of neurodegenerative diseases. I I I I 44 NEUROSCIENCE PROGRAM IIII 45 NEUROSCIENCE PROGRAM Post-doctoral researcher, researcher, Post-doctoral Dr Nae Shiozawa-West, tissue samples. examines AOFAA Professor Herbert Herzog and Associate Professor Amanda Sainsbury-Salis and Associate Professor Herbert Herzog Professor Professor John Shine John Shine Professor Oleskevich Dr Sharon Vissel Dr Bryce Adult Stem Cell Research Cell Stem Adult Leader Group in (situated neuroepithelium the adult olfactory from be isolated can cells stem Neural These neurospheres. of olfactory in the form laboratory in the and grown the nose) neuronal into grow able to are that of cells aggregates three-dimensional are structures type The identitythe olfactory within of the cell cells. and non-neuronal elusive. Our group remains cells stem these neural that gives rise to neuroepithelium of identifying, with the aim basic biology the cells studies stem of adult olfactory to needed the conditions and in determining these cells isolating and propagating example, for types in the brain, of nerve found cells the different them into transform or Alzheimer's disease. those lost in Parkinson's Research Disorders Eating Leaders Group weight obesity or severe lead to can intake of food regulation in the normal Imbalances and body weight how appetite understand major goals is to loss. One of our laboratory's may be responsible these processes that regulate pathways in brain Defects regulated. are as well as nervosa cachexia and cancer such as anorexia conditions wasting causing for in overweight or obese people. loss occurring weight to resistance the metabolic Y (NPY) molecule neuropeptide stimulating the appetite of is on the role Our main focus the and the satiety inducing hormone PYY and how these molecules coordinate the for findings have implications and body weight. Our research of appetite regulation nervosa as anorexia as well dwarfism, and osteoporosis, infertility, of obesity, treatment cachexia. and cancer Research Hearing Leader Group the the inner ear to of hearing from the mechanisms understand to strives Our research many leads to (hair cells) of the hearing receptors degeneration In the inner ear, brain. a provide can transplantation cell stem whether exploring are of deafness. We forms sensory from cells of hearing loss. Adult stem the treatment for therapy potential models of congenital mouse into being transplanted smell) are balance, (taste, organs in techniques deafness. Specialised deafness, and noise-induced deafness, age-related to combined are and hearing testing surgery, biology, transplantation cell stem cells stem of hearing. Taste in functional recovery results if transplantation determine Collaboration transplantation. effect hearing levels following on have shown a moderate extends Hospital Vincent's and St Research Cell Stem Adult for with the National Centre is underway to collaboration human tissue. An international to our animal research and physiology the anatomy determine of this synaptic plasticity using electrophysiology microscopy. and electron & Regeneration - Repair Disorders Neurodegenerative Leader Group disease, Parkinson's and treat understand better to on approaches working are We neurodegenerative devastating all of which are Alzheimer's disease and spinal disorders, and/or cells stem natural harness the brain's how to understand diseases. Our goal is to block nerve loss to cell approaches investigate nerve connections.modulate We cells' the stimulate to systems, the nervous own repair system's utilize to work and we have identified new of new nerve and their connections. We formation cells block to approaches potential discovered and we repair brain stimulate mechanisms to impacting for implications have significant outcomes Our research neurodegeneration. disorders. and spinal cord of people with brain the well-being Research Groups Research Pipetting spleen cells. IIII 47 AUTOIMMUNITY RESEARCH UNIT AUTOIMMUNITY diabetes susceptibility genes associated susceptibility diabetes with the pathogenic action of B cells an important levels of NKT in mice, cells population that is able to immune cell diseases autoimmune certain prevent and cancers and mice diabetic from on B cells arrays of aid identification to mice non-diabetic the to new genes that may contribute pathogenic activity causing of B cells 1 diabetes Type _ Identified genetic regions containing regions genetic Identified _ the Analysed_ new genes that determine whole genome expression Performed _

which may correspond to a treatment- to which may correspond of lupus in humans and form resistant kinds of treatment alternative suggests some people for the death of B (regulating system lymphocytes activatedby microbes) in some autoimmune which is impaired the survival leading to of conditions, activated harmful cells heart and defects born with congenital which impairs the identified a mutation gene's function, it is the likely suggesting of defects cause _ Discovered a new form of lupus in mice, a new form Discovered _ a mechanism in the immune Identified _ the CXCR7 gene of children Sequenced _ Program Highlights Program Program Summary Program people. For one in twenty diseases affect approximately Autoimmune times as many women they affect almost three some unknown reason, and appear without warning diseases as men. Almost all autoimmune on morbidity They and quality of life. have serious consequences can against our mounting a response of our immune system the result are defined as having human diseases are than forty More own body. treatments and many cause or probable as their definitive autoimmunity lupus systemic diabetes, 1 be ineffective. include Type Examples can disease - and Hashimoto's syndrome, erythematosus (SLE), Sjögren's all of which our unit investigates. Professor Fabienne Mackay Fabienne Professor AUTOIMMUNITY RESEARCH UNIT AUTOIMMUNITY Leader IIIIIIIII IIII People Highlights _ Professor Fabienne Mackay was an invited plenary speaker at the Research Center for Allergy and Immunology - the Japanese Society for Immunology (RCAI-JSI) International Symposium on Immunology, in Yokohama, Japan. She was also an invited plenary speaker at the Keystone conference en chemokine in Aussois, France; the Tri-conference on Cytokines in San Francisco; and the annual American Immunology meeting in San Diego. She gave the Ian Mackay oration at the 12th Australian workshop on Autoimmunity, and was a Chair and invited symposium speaker at the Australasian Immunology (ASI) conference in Canberra _ Dr Martijn Bijker was awarded a Rubicon post-doctoral fellowship from The Netherlands _ Sandra Gardam was awarded the Garvan thesis prize _ Tyani Chan won the NSW Flow cytometry prize for her work on early B lymphocyte responses _ Jessica Stolp from Dr Silveira's group was awarded the travel award to attend the Australasian Society Immunology Conference in Canberra. Dr Silveira co- organised the NSW branch Australasian Society Immunology Conference

Post-doctoral researcher Dr Martijn Bijker undertakes flow cytometry analysis of spleen cells to determine the size of T cell populations. Dr Bijker researches the role of T cells in autoimmune diseases. He is particularly interested in how stress molecules affect the immune system and the potency of T cells. I I I I 48 AUTOIMMUNITY RESEARCH UNIT IIII 49 AUTOIMMUNITY RESEARCH UNIT AUTOIMMUNITY AO FAA Dr Robert Brink and Emeritus Professor Antony Basten Basten Antony Dr Robert Brink and Emeritus Professor Dr Pablo Silviera Dr Pablo Professor Fabienne Mackay Fabienne Professor Our ultimate goal is to prevent the immune system attacking the insulin producing beta the insulin producing attacking the immune system prevent goal is to Our ultimate identify aims to the Our research 1 diabetes. Type which leads to of the pancreas, cells and persist to proteins cell beta that recognise mechanisms that allow the B cells faulty identify also aim to novel genes that control thus activate We the destructive T cells. that could findings population of B cells, and function aberrant of this the generation in humans. 1 diabetes Type or reverse prevent to new therapies the basis for form Autoimmune diseases such as lupus, myasthenia gravis and hemolytic arise can anemia diseases such as lupus, myasthenia gravis Autoimmune identify aim to the We the body. antibodies that attack rogue produce when B cells and survival, B cell proliferation, that regulate specific genes and signaling pathways against that drive antibody production as the molecules and cells as well differentiation; ourselves. By understanding against antibody responses and prevent structures foreign vaccines, improving for new strategies reveal function hope to how B cells we malignancies. B cell disease, and treating autoimmune controlling & Autoimmunity Tolerance B Cell Leader Group Autoimmune Disease Mechanisms Disease Autoimmune Leader Group of B lymphocytes in role the unappreciated concerns of study One of our main areas activating (BAFF) on the B cell factor our work from diseases - uncovered autoimmune much BAFF, is too When there by stress. affected are - and how immune responses to want damage healthy tissue. We live longer than they should and can harmful B cells drive autoimmune to immune defences know how the oversupply of BAFF corrupts be protective. to it appears conditions and why in other disorders Y (NPY), and the neuropeptide stress, on the link between research Our collaborative of the understanding building a better towards work to continues immune system and its effect cells. on immune NPY release of circumstances with heart research molecules had ramifications with some new B cell data Unexpected collaborations. via in the group of focus now new areas which are and also cancer, ImmunobiologyB Cell Leaders Group Research Groups Research PET (Positron Emission Tomography) scan showing brown fat distribution in a person. IIII 51 An over or under PITUITARY RESEARCH UNIT PITUITARY test for growth hormone doping based growth for test in of gene expression on the detection blood cells peripheral may be blood pressure, treating used for of obesity through the burden adding to its effects on energy metabolism in the burning of body fat play a role a surprising by testosterone, induced finding given that it does play a role by the female induced burning fat hormone oestrogen _ Continued to explore the feasibility of a of the feasibility explore to Continued _ medication that ß-blockers, Showed _ not that the liver does Demonstrated _ ood and reproduction. ood and reproduction.

reverse the breakdown of protein the breakdown reverse and that by glucocorticoids induced is enhanced potential this therapeutic with an androgen by co-treatment effect in sport in an of a placebo athletes evaluation on recreational thought they had been who wrongly hormone given growth a selective hormone enhances growth that aspect of physical performance, of sprint capacity (Bayesian) developed a mathematical hormone doping a growth model for any be applied to (although it could test that incorporates diagnostic test) variability and measurement biological of diagnostic markers active pituitary gland can lead to a range of diseases from dwarfism of diseases from a range active lead to pituitary gland can in muscle wasting, obesity and mood disorders, infertility, to children of the the role is understanding in adults. The Unit's major focus diabetes and physical composition body metabolism, pituitary gland in controlling such as function. health problems Its effects underlie the many key (muscle wasting). and sarcopaenia osteoporosis obesity, Program Overview Program body growth, hormones that control key The pituitary gland produces m metabolism, appetite, strength, Program Highlights Program hormone can growth that Showed _ demonstration the first Completed _ that evidence the first Collected _ with the Bone Program, In collaboration _ Professor Ken Ho Ken Professor

PITUITARY RESEARCH UNIT PITUITARY Leader IIIIIIIII IIII _ Professor Ken Ho was awarded the Asia- _ Dr Vita Birzniece received a Poster Prize Dr Paul Lee, endocrinologist and PhD student, reviews a Oceania Medal by the British Endocrine from the US Endocrine Society, the PET (Positron Emission Society, invited as Keynote Speaker by Australasian Branch of Women in Tomogoraphy) scan. Dr Lee analyses RNA in brown fat to the Irish Endocrine Society, invited to Endocrinology Award from The understand how it develops. serve on the Annual Meetings Steering Endocrine Society of Australia and a One day, brown fat may be a Committee of the US Endocrine Society travel award from the Growth Hormone target for treating obesity. and joined the Editorial Board of Research Society Endocrinology _ Dr Udo Meinhardt, a Postdoctoral Fellow, _ Dr Paul Lee was awarded a Postgraduate was awarded a prize for the best Clinical Medical Scholarship by the NHMRC for Research at the International Growth studies towards a PhD on the metabolic Hormone and IGF Congress in Genoa effects of ß-blockers. He was the _ Ms Jennifer Hansen's work was selected recipient of the Wiley Blackwell Clinical by the US Endocrine Society for Special Excellence Award from the Royal Media Interest. The work was reported Australasian College of Physicians; the by a range of agencies including the Young Investigators Award by the Times, CBS News, Fox News, The Internal Medicine Society of Australia Australian, Discovery and Forbes magazine and New Zealand; and received Travel Grants from Royal Australasian College _ Dr Akira Sata was awarded an Australian of Physicians, The Endocrine Society of Government Endeavour Fellowship to Australia and the Growth Hormone undertake Postdoctoral studies on sex Research Society steroid modulation of Growth Hormone signalling _ Dr Jing Ting Zhao filled the position of Scientific Head, bringing strong molecular skills to the Unit I I I I 52 PITUITARY RESEARCH UNIT IIII 53 PITUITARY RESEARCH UNIT PITUITARY We are addressing the metabolic significance of therapeutic blockade of the of therapeutic significance the metabolic addressing are We vital energy for nervoussympathetic in providing plays which system, a major role functions. of a host of the sympathetic nervous Stimulation increases system output and fuel cardiac increased that lead to responses and metabolic cardiovascular Our project stimulation. by the beta-adrenergic mediated utilisation. These actions are rate, metabolic adiposity by reducing increase that beta-blockers the hypothesis tests use, their actions on of their widespread Because capacity. and exercise oxidation fat Conversely, of obesity in the community. the burden may worsen energy metabolism loss. weight judicious use of agents that activate may cause the system We are aiming to develop new approaches for the detection of GH doping and studying the detection for develop new approaches aiming to are We its effects on performance. forms and the different proteins blood GH responsive the merits of have evaluated We that the most have found of GH abuse. We detection for isoforms, of GH, called and that GH is taken after weeks several GH for detect can of these markers promising should enable is also used. This sensitive when testosterone is even more one marker are we the CSIRO, with In collaboration using these tests. be detected cheats to more develop a gene analysis aiming to and gene pathway gene profiling utilising microarray have found We blood cells. of white profiling based on gene expression fingerprint test only to but this benefit is confined performance time that GH enhances the first for or endurance. power strength, sprint capacity and not major funding worth over one million dollars over 3 years The Unit has also received study. the gene expression Anti-Doping Agency for the World from Drugs and Obesity Nervous System, Sympathetic Work from the Unit has shown that Growth Hormone (GH) plays a major role as a Hormone (GH) plays a major role that Growth the Unit has shown from Work how the GH investigates The ongoing work adult life. hormone throughout metabolic and what disease its disturbance arise from what health problems is controlled, system a hormones exert that sex have discovered the use of GH. We benefit from can states how influence to likely that these are postulate and we major effect on the GH system hormone oestrogen have shown that the female We process. the metabolic GH controls the action boosts, of GH. Under active blocks, while male hormone testosterone SERMs, which are called of compounds consequences the metabolic investigation are and of osteoporosis the treatment for widely used compounds, oestrogen-like synthetic with male GH benefit of combining the potential also explores The work cancer. breast muscle wasting. treat hormones to and molecular mechanisms the cellular addresses in the laboratory work Complementary modify the action steroids of GH actionby which sex identifying and novel GH hormones of how female our understanding extends project parallel genes. A regulated GH, in the to related a pituitary hormone that is structurally with prolactin, interact with the of lactation and mammary development in collaboration regulation Program. of the Cancer Development Group (GH) Doping Hormone Growth Research Groups Research and Health Metabolism Hormones,

IIII 55 CORE RESEARCH FACILITIES RESEARCH FACILITIES CORE applies techniques derived from disciplines such as derived from applies techniques

runs Garvan clinical research projects such as those that look projects runs Garvan research clinical (ABR) holds mouse production colonies under clean room (ABR) colonies holds mouse production contains the Affymetrix Microarray System that is used to compare that is used to System the Affymetrixcontains Microarray houses equipment that can detect and analyse genetic sequence variations and analyse detect sequence houses equipment that can genetic CORE RESEARCH FACILITIES RESEARCH FACILITIES CORE applied mathematics, statistics and computer science to understand, organise and organise understand, to science applied mathematics, and computer statistics data, and microarray clinical This includes the housing of both analyse data. biological querying and analysing these datasets. for programs and the building of computer Stuart data, cancer managing clinical for include Cansto of these programs Examples - a microarray management and Garvan's GeneSpring WorkGroup animal records for by the Australian Australia and analysis is used across environment. CanSto archiving management. information Garvan's all their clinical for Collaboration Cancer Prostate researchers for results experiment server houses microarray GeneSpring WorkGroup Australia. across at the effect of hormones (e.g. growth hormone, sex steroid hormones, insulin) on steroid hormone, sex at the effect of hormones (e.g. growth involved in pharmaceutical volunteers also monitor Staff systems. metabolic different medications. osteoporosis trials, such as those for clinical Centre Wills Bioinformatics Peter such as gene losses, mutations, expression, and methylation on a large scale. A diversity scale. on a large and methylation expression, such as gene losses, mutations, within and outside the research facilitate to is available within the facility of platforms aimed at high-throughput, sensitivity, Garvan are The goals of the facility Institute. analysis and methylation sequencing effectiveness. In addition to and cost accuracy in NSW. all researchers is now a mouse genotyping service available for services, there Gene Chip Facility genes of find potential in tissue samples. It is used to the levels of gene transcripts then be further of which can Unit that can analysed the subsets in the ACRF interest, the system. establish to numbers of samples. Garvan in Australia the first handle large was BioResources Australian The Biological in NSW. organisations Garvan research medical for and other conditions to zones holding in specialised experimental ABR for from mice Facility receives Testing enable quality animal-based research. Facility Research Clinical Australian Cancer Research Foundation (ACRF) Facility for the Molecular Genetics the Molecular for Facility (ACRF) Foundation Research Cancer Australian of Cancer IIIIIIIII in medical of being competitive is an important component Technology equipment state-of-the-art contain facilities research Garvan'sscience. core to experiments the necessary perform that enables our scientists to manager oversees A highly trained disease processes. understand better researchers. external to also available which are the facilities Flow Cytometry Facility encompasses instruments used for cell analysis and provides a cell sorting service to allow the separation of up to four populations of cell types from any body fluid or tissue suspension. Through the use of laser, optical and fluidics technology the pure population of cells can be separated on the basis of multiple phenotypic and functional characteristics, and then grown as pure cultures, used to extract RNA or DNA for genetic analyses, or implanted into animal models, for functional assays and therapeutics. Pieter Huveneers Molecular Imaging Facility consists of a number of state-of-the-art microscopes which, using a variety of fluorescence based techniques, are capable of imaging tissue, cells, intracellular organelles and even multiple individual molecules in live cells. Using techniques such as Total Internal Reflection Fluorescence (TIRF) microscopy we are able to image events occurring on or near the surface of a cell. Using laser Manager of the Flow scanning confocal microscopy we can precisely image 'slices' of samples which can be Cytometry Facility, Mr reconstructed into a 3D representation for analysis. These provide our scientists with Christopher Brownlee, checks the laser alignments on the best possible means of identifying where and when molecules of interest are in FACSVantage (a cell sorting normal tissue and how this may differ in disease. flow cytometer). I I I I 56 CORE RESEARCH FACILITIES IIII 57 MANAGEMENT HIGHLIGHTS MANAGEMENT dispersed research community by community dispersed research versions of new and upgraded releasing and CryogenicsGrants the Publications, Garvan's Additionally, systems. storage solution, CanSto, research own cancer at Royal North Shore installed was and Charles Hospital Concord Hospital, in Perth Hospital Gardner applied by establishing Garvan researchers of in the area with CSIRO collaborations biologymolecular imaging and structural and diagnostic biotech international develop therapeutic to companies neurodegenerative for tests response novel cancer discover disease and to biomarkers Research Medical $30m pre-seed a advance to Fund Commercialisation and a diagnostic therapeutic promising 2 diabetes of Type in the area project including in intellectual matters property and what is necessary searching patent findings into develop early stage to projects attractive clinically _ Helped support geographically a growing, available to Expanded the technologies _ with agreements several Completed _ the to funding proposals two Submitted _ of Garvan training Continued researchers _

Occupational Health and Safety Occupational that Garvan induction ensure to system environment, working safe a remains of two automated including: installation (AED) units to defibrillator external working a safe further enhance environment; of a site development flip chart,specific emergency which has points; at key and been installed all of risk assessments for completion known Institute's on the chemicals inventory chemical near Moss Vale, BioResources, Australian of 14 relocation involving the staged and Garvan mice 12,000 staff, equipment,miscellaneous as the as well 1,500 of another receipt co-ordinated The seven partner institutes. from mice building utilises state-of-the-art systems. and caging operating Builders Association the NSW Master One facility. the Moss Vale (MBA) for health building, the best $10 - 25 for as the NSW MBA's million. The other Energy Efficiency Building Award, to desire Garvan'sreflecting express have a low impact, environmentally friendly facility. opening prior to systems communication support to the new animal facility, and to operations efficient large-scale access data improved provide at Garvan include voice-over-IP to the animal breeding services to (VOIP) building in capacity in Moss Vale, facility growth future for _ Developed and implemented an on-line Developed and implemented _ Opened our new animal facility, _ from awards two prestigious Received _ / and data operating Upgraded _ system telephone the PABX Upgraded _ MANAGEMENT HIGHLIGHTS MANAGEMENT of the St Vincent's Research Precinct, Research Vincent's of the St Garvan in the completion participated and occupancy of the Lowy Packer Building, housing the Victor Chang and several Institute Research Cardiac groups research Vincent's of St of outlining the operation Agreement various essential services, which will be the Garvan between and Lowy shared Buildings, such as the loading Packer generators and emergency dock, stores as facilities and Media Prep Glass Wash the Precinct for facilities integral including: footprint, our carbon reduce energy efficient of lighting to upgrade tubes; of installation fluorescent activate lighting to movement detectors and adjustment use spaces; in irregular systems air conditioning the central to various for and Media Prep) Wash an including within Operations, groups improved space, Engineering expanded and Workshops Instrument Repair groups other for desk space expanded vapour phase cryogenic vessels in the demand from to response and stable secure more for researchers samples. This biological for storage leading edge technology by is supported and tracking (for application a software managing samples), designed and developed by Garvan IT

IIIIIIIII part of the development As_ an integral Management a Precinct Developed _ enhanced significantly and Relocated _ on energy saving initiatives to Focused _ by Glass (vacated space Redeveloped _ two 90,000 vial capacity Received _

IIII

59 , AO FAA BUSINESS DEVELOPMENT BUSINESS , AC Board Chairman, GarvanBoard John Shine Professor Business Development Business Development Advisory Council The Business Development Advisory includes several (BDAC) Council and the biotech from representatives industries. pharmaceutical (Chair) Dr Lisa McIntyre L.E.K.Director, Consulting Bill Ferris Executive Director, Garvan Director, Executive Moore Dr George Director External Dr Merilyn Sleigh, Director External Carre, Peter Australia Burrill CEO, Christina Hardy, Business Development & Director, Garvan Affairs, Legal John Dakin, Garvan Officer, Chief Operating Dr Robert Brink Immunology Program, Leader, Group Garvan BUSINESS DEVELOPMENT BUSINESS The Business Development team, under the leadership of Christina Hardy, engages with Hardy, under the leadership of Christina The Business Development team, organisations sector academic partners and with other and biotech the pharmaceutical the development of new closer towards one step discoveries Garvan's research take to closely with Garvan the Business scientists, Working tests. and diagnostic treatments monitoring from all aspects of commercialisation for is responsible Development team identifying of intellectual property, activities maximising early capture to research and managing commercial opportunities,and negotiating pharma/biotech market applied establishes Importantly the Business Development team agreements. which greatly who have additional technologies with organisations collaborations use. clinical be developed for to Garvan's for breakthroughs the potential increase treatment, covering families 39 patent The Garvan portfolio comprises patent categories. diagnostics and screening Nordisk and Novo G2 Therapies Schubert, by Dr John chaired develops and which company, is a private G2 Therapies at Garvan inflammation. Founded in for antibody-based therapeutics commercialises Nominees. and Baron include AMWIN 2002, major investors development and the signing of a major research, In early 2006, G2 announced of the Novo Nordisk. The terms company with Danish healthcare agreement licensing payments, and payment, milestone include an upfront success-based agreement therapeutics. on commercialised royalties the lead anti-C5aR monoclonal advanced have recently and G2 Therapies Novo Nordisk holds 2008. Anti-C5aR antibody treatment trials in late human clinical antibody to arthritis lupus, rheumatoid including conditions a number of inflammatory for promise diseases. autoimmune and other IIIIIIIII Overview I I I I I I I II GARVAN COMMUNITY

Life Governors Partners for the Future Mr John & Mrs Mary Miller Miss Helen Morgan Allind Pty Limited Mrs M Abercrombie Mr Peter Olive Amadeus Energy Limited Mrs Margaret Adams Mrs Lesley Powell Mr John Armati Dr W Michael Baker Mr George Quigg Australian Cancer Research Foundation Ms James Belger Mrs Judy Radecki ASX-Reuters Charity Foundation Mr Peter Binnie Tanya Roddan Australian Deafness Research Foundation Ken Bloxsom In memory of Sonia Gabrielle Saba-Losey Australian Securities Exchange Ms Linda Booth Miss Vi Saint The Blundy Family Mr Earle & Mrs Marlene Boutwell Ms Coral Saunders Coca-Cola Amatil Mr Alan & Mrs Anne Boyle Miss Thelma Shepherd Mr Charles P Curran AC Ken & Betty Brown Mrs Cynthia Southwell The Curran Foundation Mrs Judith Clark Miss H Stockman Lady (Mary) Fairfax AC OBE Mrs Madeline Coelho Mr Leonard Towers Ferris Family Foundation Mr Jock Crooks Mrs Judith Wheeldon AM Mr Laurence S Freedman AM Mr Rodney F Darke Mrs Jean Whittaker Miss Felicia D Garvan Ms Cristine Davison Dr Eva Wicki Mr James Patrick Garvan & Family Mrs Marlene Dixon Ms Faye Margaret Williams George Patterson Pty Limited Mr John Dobies Mary and Herbert Morris Mr and Mrs B & A Ginges Mrs Phillipa Dorin Ms Jacquie Cole Mr Paul & Mrs Judy Hennessy Ms Daile Falconer Dr Norman Marshall HIH Insurance Ltd Mr Gabriel & Mrs Joan Farago Mr Pieter H Huveneers Ms Jan Foster Volunteers Mrs Virginia Kahlbetzer Mr Michael & Mrs Joy Foulsham Janet Barkell Mr T Kennedy AM & Mrs C Kennedy Elizabeth Fyffe Kaye Blaiklock Mr Ralph and Mrs Lorraine Keyes Mrs Carmel Gillett Deirdre Blakemore The Kinghorn Foundation Miss Flo Greene Graham Curtis Mrs Mabs Melville Dr A.N. Gyory Margarita Field MLC Community Foundation Mrs Jean B Hale Lyndie Hemery National Australia Bank Ltd Dr Bronia Hatfield Mrs Edna Hutton Dr Graham O'Neill Ms Heather Patricia Hindle Lynne Jones Order of the Eastern Star Chapter No. 38 Mr J K L Hooton Juliet Kirkpatrick Mr K Packer AC Miss V Jenkins Janice Lee The Paramor Family Byram & Deborah Johnston John McInerney The Ritchie Family Mrs Florence Jones Margaret McInnes Mr Tim and Mrs Sally Sims Mrs Virginia Kahlbetzer Bob Neilson Mr Robert Strauss MBE Ms Lili Koch Joan Neilson Mr Laurie Sutton Roberta Lauchlan and Barry Thompson Jean Pushong The Lady Proud Foundation Mr Keith Line Julie Reid The Petre Foundation Mrs Adell Littlejohn Philip Twigg Westfield Holdings Ltd Ms Maria Lydaki Bill Upton E J Whitten Foundation Denise Maddocks Mr Ray Williams WJ and PA McNamara A thank you also to the volunteers from Mrs Mabs Melville ASIC, MLC, NAB, and BNP Paribas who assisted us with the 2008 Open Day. I I I I 60 GARVAN COMMUNITY IIII 61 AC OBE AC GARVAN COMMUNITY GARVAN AM Mrs Janice Gibson Mrs Janice Research Fund Research Mrs J Doyle Mr Phil Durney Eger Mr Andrew Eli Lilly Australia J Elliott Mr Patrick and Foundation Ernest Heine Family Evans Mr Andrew Evans Mrs Margaret Lady (Mary) Fairfax Mr Jonathon A Feller G Fenton Mr Tom Foundation Family Ferris Ms Jane Forster Mr Michael & Mrs Joy Foulsham Research Prader-Willi for Foundation Fyffe Elizabeth Gadens Lawyers Pty Sydney Ltd Gale Eric & Tonia Mr Justin H Gardener Dr William Garrett Australia GlaxoSmithKline John Glennie Joe for Cherie Glick and family Golding Mr Cyril Goldsmith Mrs Elizabeth graysonline.com Foundation The Greatorex Green Sharon Limited Partners Gresham Mr J Grice Mrs Enid Griffin Mrs R A Gross H Gruy William A and Laura Mr & Mrs G F & B C Gschwenter Dr Jenny Gunton Oncology (GO) Gynaecological Alan Hellicar PtyH Kallinikos Limited Mrs Jean B Hale Foundation Hore & Wallace The Jessica Mrs Ann Hanson Mr Loftus Harris Charity Day Fund Employees' Provident and Research Science Mrs Thelma Susan Bonner Mrs D Bonser Bowers Ms Margaret Ms Louisa Boyle Mr and Mrs G & C Bradley Bright & Dr Desmond Bright Dr Ruth & Betty Brown Ken Buchanan Mrs Kate Mr G Bushby Buwalda In Memory of Yvonne CAF Australia NSW Council Cancer NSW Institute Cancer Mrs Helen Callander Rogers Memorial and Steve Carol Castle Harlan Inc Chapman Mr Andrew Mr Chris Chapman & Dr Cath Chapman Chapman Mr Craig Chester Ms Janet Foundation Ramaciotti Clive and Vera Ms Melinda Conrad Foundation The Corio Costigan Mr Stanley & Susan Courtenay Brett Cropley Mr Richard CSR Limited Foundation Australia Cancer Cure Mr & Mrs R Cusick Limited Co-operative DairyFarmers Mr Rodney F Darke David Mr Peter J G & Dr J R Davis Professor Mr Robert Davis De Saxe & Coleen Mr & Mrs Tony and Trade Affairs Department of Foreign Department of Innovation, Industry, Trust Research Australia Diabetes Geoff and Dawn Dixon Ms Rochelle Dizon Clients Dominion Private Commission Scheme Australian Government Department of Australian Information Communications, and the Arts (DCITA) Technology Australian Securities Exchange Australian Quilters Avalon Bain & Company Mr Klaus Bartosch Basten Antony Professor Mr Douglas Battersby Mrs Marie Bennett Betts Miss Tania Community Program BHP Billiton Mrs Kaye Blaiklock BNP Paribas Foundation BNP Paribas Mr Roy L Bockholt Mrs Gay Boersma Ascham School Foundation Research Cancer Australian Foundation Deafness Research Australian Association Inc Ladies Variety The Australian Council Research Australian Fund Health Research Rotary Australian Securities & Investments Australian A W Edwards Pty Limited A W Edwards Mr Chris M Abbott Accenture Energy Limited AGL Michael Ahrens AinsworthMr Len Fund Ake Ake Rolled Products Australia Alcoa Foundation Alcoa Allen & Unwin Pty Ltd Amadeus Energy Limited Express American AMP Foundation Mr Neil Anderson of the Program Anti-doping Research Support ARC/NHMRC - FABLS Network Garvan Supporters Garvan Research Foundation CEO, Ms Carole Renouf, with MLC CEO, Mr Steve Tucker and Manager of Garvan's Flow Cytometry Facility, Mr Christopher Brownlee. The MLC Community Foundation has pledged $1 million to the facility over 5 years.

Ms Betty Haugh Mr Robert Landeros National Institutes of Health Mr & Mrs Bill & Alison Hayward In Memory of Michael Ison Large The N E Pendergast Charitable Trust Fund Mr Alan Heggie Ms Nita Lavigne Mr James Nilson Meredith Hellicar Mr Jeremy Layman Mr & Mrs Leigh & Binnie Norman Mr Paul & Mrs Judy Hennessy Lions Club of Hawkesbury Bells Line Inc. Novartis Pharmaceuticals Australia Dr G J Hiatt Lord Mayor's Charitable Foundation The NSW Cancer Council Mr I Holmes (Melbourne) NSW Department of Health & Ageing Dr & Mrs Francis & Marie Hooper Mr Michael Lowe NSW Office for Science and Medical Mr J K L Hooton Mr Bramwell Lucas Research Ms Jessica Hore Ms Maria Lydaki Nuclear Medicine and Bone Densitometry, Mrs Sue Howieson Mrs Ann Macintosh SVH Mrs L A Hudson Macquarie Group Foundation Mr Michael O'Dea AM & Mrs Marianne Stanley Hunt OAM Mallesons Stephen Jaques O'Dea Mr Robin & Mrs Beatrice Hutcheon Mr A J & Mrs S A Malouf Mr J O'Farrell Mr Pieter H Huveneers Mr Roy Manassen Dr Graham O'Neill Mr & Mrs M Isaacs The Mandarin Club Orange & District Breast Cancer Support Mr Phill Isaacs Mr R & Mrs S Maple-Brown Order of the Eastern Star Chapter No. 67 The Hon Justice Peter M. Jacobson Dr Karen Mardel Mr Wayne O'Toole Mr R Jarvis Mr Philip Mason & Ms Alexandra Joel Pacific Equity Partners John & Connie Kennedy Charitable Trust The Hon John & Mrs Dympna Matthews Miss Winnie Pang John Lamble Foundation Mr Peter McGovern The Paramor Family John T Reid Charitable Trusts WJ and PA McNamara Park Hyatt Sydney Mrs Sheila M Johnstone Medical Benefits Fund (MBF) Ian Paul Mr Alan Joyce Medtronic Australasia Pty Ltd Perpetual Trustees The Juvenile Diabetes Research Mrs Mabs Melville Pfizer Australia Foundation (JDRF) Merck Sharp & Dohme (Aust) Pty Limited Pfizer Global Research and Development Mrs Virginia Kahlbetzer The Michael & Andrew Buxton Foundation Pfizer International Lady Catherine Kater AM Mr Neill Miller Prader-Willi Syndrome Association of Mr & Mrs Patrick & Beryl Keane Mrs Wendy Millhouse NSW (Aust) Inc Mrs Helen Keir MLC Community Foundation Premier Media Group Professor Geoffrey Kellerman AO Mr & Mrs R & A Mole Pricewaterhouse Coopers Foundation The Ken & Alse Chilton Charitable Trust Geoff & Jan Moles Prostate Cancer Centre, St Vincent's Mr T Kennedy AM & Mrs C Kennedy Mr Warren Morley Hospital Mr Raymond Kent Ms Lesley Morrison Prostate Cancer Foundation of Australia Mr Ralph and Mrs Lorraine Keyes Motor Neurone Disease Research Institute Public Trustee NSW The Kinghorn Foundation of Australia Qantas Airways Limited Mrs A Kirby MSM Milling Pty Ltd Quota International Mr W Bruce Kirkpatrick & Mrs Juliet Mr Peter Murphy Mrs E Ramsden Kirkpatrick Mr S Murray Mr Roy Randall Mr John T Kneeshaw Mr J Muysken Rebecca L Cooper Medical Research Mr Philip Knox National Breast Cancer Foundation Foundation KPMG National Health and Medical Research Mr Jean Redman Ms Josie La Spina Council Brad & Lisa Rees The Lady Proud Foundation National Institute of Complementary Retire@Ease Financial Planning Medicine I I I I 62 GARVAN COMMUNITY IIII 63 GARVAN COMMUNITY GARVAN Dr Nae Shiozawa-West with discusses her research who has Mrs Rosemary Pryor, Garvan's $1 million to donated Program. Neuroscience AM Carrington Lawn and Marjorie Grace Wilshire Bequests Gloria M Backhus of the Late Estate M Bismire Brenda of the Late Estate Denzil de Ferrars of the Late Estate Milly Dinjaski of the Late Estate Lawn Charles Edward of The Late Estate McAllister Leslie of the Late Estate Henry R McQuirk of the Late Estate Phyllis Maude O'Hanlon of the Late Estate Josephine Ryan Babette of the Late Estate W Steed George of the Late Estate M Trunshnig Charlotte of the Late Estate Betty A Williams of the Late Estate Mr Alan Whitfield Foundation E J Whitten Kathrin Nell A In Memory of the Late Mr William Wilson Witchery Emil Witton Foundation Family Wood Mr J & Mrs L Woolf Wright Mr Andrew Wright Ms Pamela J Wright Dr Stan (UK) Trust XLP Research Mr Ralph W Young Young Mr Stanley Mr Peter Unwin Mr Peter Institute Research Victor Chang Cardiac Coffee Vittoria & Data Voice John & Megan Wade Pty Civil Engineering Ltd Wade Walder Mrs Caroline Dr JR Warneford Wedutenko Ms Alexandra Banking Corporation Westpac Mrs Judith Wheeldon FAA and Roslyn Horin AO Mr George Risk Mr George Mrs Judy Roach The Rodney & Judith O'Neil Foundation Mrs Deanne Rooz Rosemary Foundation Pryor Rosmain Ms Kelly Club of Hurstville Rotary Foundation Charitable Roth Mr Garry Rothwell Chemist Roy Young Hall Trust RT Mrs G Ryan Mr Martin Sachs Sanofi-aventis Mr D & Mrs A Saul Mr L Seaman See Mr Graham Jan Shaddock Mr & Mrs T & J Shanahan Mrs D Shannon Mrs Lindsey Shaw Mr David Shmith Simons Mr Richard Trust Charitable Skipper-Jacobs Joseph Skrynski Swiss National Fund Swiss Women for Ultrasound Sydney OBE & Mrs Mimi Tait Mr Nick Tait Investments Limited Thomas Hare Turner Mrs Margaret Mrs A Udy University of NSW Mr M Slavich Smith Mr Graham Mr Barry Smorgon Mrs Shirley Smyth Snoeys Mr Frank & Sabrina Snow Mr & Mrs George Mr Neil Spitzer Clinic Foundation Vincent's St Miss Alison Stephen Industries Strategic Strong Ms Joyce Rob Sutherland Professor I I I I I I I I GOVERNANCE I IIII 65 GOVERNANCE and a member of the Board of Trustees, of and a member of the Board as a as well Sydney Universityof Western of Governors of member of the Board Ms Dame Australia. University of Notre Businesswoman of NSW Telstra was Foley the awarded in 1998 and was the Year service to Medal in 2003 for Centenary society in business leadership. Australian the Boards down from stepped Ms Foley of the Garvan and Garvan Institute 2008. in March Foundation Research Lisa McIntyre for Minister by the Federal Nominated Health is a partner with the Dr Lisa McIntyre firm LEK Consulting consulting strategy Sciences Life Asia Pacific and head of LEK’s She has over 15 years consulting practice. the biotechnology sector for experience with over 100 different and has worked clients sciences biotechnology and life on the challenges primarily focusing innovation. with commercialising associated in 2002 Sydney to relocated Dr McIntyre co- States nine years in the United after where practice Sciences Life heading LEK’s leading she advised many of the world’s She is also a biotechnology companies. and AtCor Ltd Capital of Biotech director PtyMedical Ltd. Paramor Greg by the GarvanNominated Research Foundation in the real has been involved Paramor Greg funds management and property estate 35 years. approximately industry for Managing appointed was Mr Paramor of the Mirvac following Director Group of the James Fielding the acquisition in January 2005. He is the past Group of Council of the Property President and the Investment Funds Australia a He is currently Association of Australia. Lisa McIntyre Greg Paramor Greg Graham J Bradley Graham Nicholas Curtis Mary Foley Graham J Bradley Graham by the GarvanNominated Research Foundation company is a professional Bradley Graham Chairman of is Mr Bradley director. HSBC Bank Limited, Corporation Stockland and Anglo American Limited Australia 2003 he 1995 to From Limited. Australia of Perpetual Managing Director was partner of He is a former Australia. management McKinsey & Company, national and a former consultants, Dawson. Mr managing partner of Blake Chairman of appointed was Bradley June 1999 in Foundation Garvan Research in and joined the Garvan Board Institute November 1999. Nicholas Curtis of by the Trustees Nominated Hospital Vincent's St in Nicholas Curtis has a background investment banking and the resources Chairman of He is Executive industry. an Australian Limited, Corporation Lynas earths. specialising in rare public company as Chairman of appointed Mr Curtis was Health & Mater Vincents of St the Board 2004 and also serves in August Sydney of Charity of the Sisters as a director Health Service. Mary Foley of Charity by the Sisters Nominated Marythe position of the Chief held Foley & Mater Vincents St Officer, Executive until early 2008. Ms Foley Health Sydney the National Health Practice is currently at PricewaterhouseCoopers. Leader Deputy positions include Head, Previous NSW Department of Health and Executive and of Health Policy NSW Office Director, management positions senior executive health care Nickless private Mayne for is Deputybusiness. Ms Foley Chancellor AC AC Bill Ferris Bill Ferris Martin Hoffman Bill Ferris Bill Ferris Chairman Vincent's of St by the Trustees Nominated Hospital Chairman of the is Executive Bill Ferris one of Equity Group, CHAMP Private groups, capital leading private Australia's expansion capital, venture providing buyout funding and management capital of the is Chair Ferris Mr in Australasia. and Garvan Research of Medical Institute Chair of the Health appointed recently as Advisory Fund Board and Hospitals Government's Nation- part of the Federal initiative. Former Building Funds include: Chairman, Australian directorships Austar (Austrade), Commission Trade and Limited Communications United Pty Other current Ltd. Resources Bradken Garvan include: Director, directorships Foundation. Research in the made an Officer was Mr Ferris services to in 1990 for of Australia Order industrythe export and in 2008 was of Australia in the Order made Companion activities and his role his philanthropic for equity of the private in the establishment sector in Australia. Martin Hoffman Treasurer of Charity by the Sisters Nominated Martin Hoffman is the principal of Ulysses of advisory services a provider Ventures, digital early-stage and seed investment to He was media and technology companies. a Mobile Limited, CEO of Loop previously of mobile chat and provider listed and servicescommunity internationally, internet largest of NineMSN, Australia's He has also held senior media company. Media with Fairfax management roles and Optus. Garvan Institute Board Garvan Institute Sister Carol Pedersen RSC John Shine AO FAA Bernadette Tobin

Warren Scott Peter J Smith Ronald Trent

director of a number of companies, John Shine AO FAA Bernadette Tobin including the National Breast Cancer Appointed by the Garvan Institute Board Nominated by the Trustees of Foundation. He is a Fellow of the Australian St Vincent's Hospital Professor John Shine is Executive Director Property Institute and a Fellow of The of the Garvan Institute of Medical Associate Professor Bernadette Tobin is Royal Chartered Institute of Surveyors. Research and a board member of the Director of the Plunkett Centre for Ethics Sister Carol Pedersen RSC Garvan Research Foundation. He is at St Vincent's Hospital, Sydney, and Nominated by the Sisters of Charity Professor of Molecular Biology and Reader in Philosophy at the Australian Professor of Medicine at the University Catholic University. Dr Tobin is Honorary Sister Carol Pedersen graduated as a of NSW, and a director of many scientific, Ethicist at the Children's Hospital at trained nurse at St Vincent's Sydney in research and medical bodies throughout Westmead, Honorary Associate Professor 1963 and is a Sister of Charity. She holds Australia, including the recent ex- in the Faculty of Medicine at the University a PhD from UNSW and a BSW (Hons 1) Chairman of the National Health and of Sydney, and Conjoint Associate from the same institution. She also holds Medical Research Council (NHMRC) and Professor in the School of Medicine at the an Advanced Diploma from the Sydney until 2006 a member of the Prime University of New South Wales. She College of Homoeopathic Medicine, and Minister's Science, Engineering & served for three triennia on the Australian has completed postgraduate work, Innovation Council (PMSEIC). Health Ethics Committee, a principal obtaining an Associate Diploma in committee of the NHMRC. She also Advanced Homoeopathic Medicine. For Peter J Smith chaired the drafting group which prepared over 20 years Sr Carol was a member of Nominated by the University of NSW the first Code of Ethics for Catholic Health various Human Research Ethics Professor Smith is Dean, Faculty of and Aged Care Services in Australia. Committees, and was active at national, Medicine, the University of New South state and local levels in the development Ronald Trent Wales. He specialised in cancer medicine of Alcohol and Drug Services. Nominated by the Federal Minister and research following study in Australia, for Health Warren Scott USA and Germany. He has held senior Nominated by the NSW Minister for Health hospital management posts in Brisbane Ronald Trent is Professor of Molecular and Melbourne, and senior academic Genetics, University of Sydney and Head Warren Scott is a director of Citigroup appointments at the Universities of of the Department of Molecular and and is General Counsel and Managing Queensland, Melbourne and Auckland. Clinical Genetics, Royal Prince Alfred Director in Australia. He is Chairman, He has served in a consulting role to Hospital. He is the Chairman of the Woolcock Institute of Medical Research, Government, including as Chair of the Advisory Committee for the University's as well as a delegate to the Australian recent Inquiry into Vietnam Veterans recently formed Forensic Medicine & American Leadership Dialogue, the Law Cancer Incidence and Mortality. Professor Science Network. He has been a member Society of New South Wales, the Smith is currently a Director of St Vincents of the NHMRC Research Committee since American Bar Association, the New York & Mater Health Sydney, NewSouth 1997 and has been Chairman of the Bar Association and the California Bar Innovations, MedSys Assurance (NZ) and a NHMRC Human Genetics Advisory Association. Warren is admitted as a number of research centres and institutes. Committee as well as a member of the solicitor in New South Wales and as a NHMRC Council since 2006. lawyer in New York and California. I I I I 66 GOVERNANCE IIII 67 GOVERNANCE James Ethics Centre and two scholarship and two James Ethics Centre Mr Clark joined the foundations. in 2005 and stepped Board Foundation down in 2008. Melinda Conrad Managing is former Melinda Conrad store of the retail and Founder Director her to Prior Warehouse. chain, Conrads she held of Conrads, establishment at Harvard Business management roles Ms Conrad School and Colgate-Palmolive. of the Australian is also a director joined Ms Conrad Orchestra. Brandenburg in 2003. Board the Foundation Geoff Dixon of is on the Boards Geoff Dixon and Media Holdings Limited Consolidated He is also Chairman of the Limited. Crown Consolidated of both Risk Committees Limited. Media Holdings and Crown down in November stepped Mr Dixon eight years as Managing 2008 after of Officer and Chief Executive Director joined Airways Mr Dixon Qantas Limited. in 2008. Board the Foundation Geoff Dixon Melinda Conrad Melinda Conrad AM AM Philip Marcus Clark Philip Marcus Alec Brennan leading the practice group in Asia Pacific group leading the practice joining Egon Zehnder to 3 years. Prior for & at Procter Jane worked International in Gamble in sales and then marketing Jane has an US and Australia. the both Harvard School and a Business MBA from Ms Smith College. Bachelor of Arts from in 2007. Board Allen joined the Foundation Alec Brennan of pursues a portfolio Alec Brennan Until interests. profit for business and not CEO and Managing 2007, he was March He is Chairman of of CSR Limited. Director Chairman Limited, Emeco publicly listed owned PPI in privately and co-investor Chairman of Tomago and Limited Aluminium Pty of the He is a Fellow Ltd. University of Sydney and Chair of Senate Mr Brennan of its committees. several in 2000 and Board joined the Foundation down in 2008. stepped Clark Philip Marcus Originally trained in law and management,Originally trained growth Philip Clark has led the successful of Australia’s and development of two Ellison and law firms, Minter largest Jaques as Managing Mallesons Stephen Mr Clark is a member of and CEO. Partner Advisory Chairman Council, the JP Morgan Endowment Fund of the Higher Education of ING and a director Advisory Board CRI Asset Management Management Ltd, M+K Lawyers St Limited, Holdings Ltd, Jane Allen Graham J Bradley Graham Graham J Bradley J Bradley Graham Chairman company is a professional Bradley Graham is Chairman of Mr Bradley director. HSBC Bank Limited, Corporation Stockland and Anglo American Limited Australia 2003 he 1995 to From Limited. Australia of Perpetual Managing Director was partnerof He is a former Limited. management McKinsey & Company, national and a former consultants, Dawson. Mr managing partner of Blake Chairman of appointed was Bradley in June Foundation Garvan Research 1999 and joined the Garvan Institute in November 1999. Board Jane Allen of Egon Jane is the Managing Partner office, Sydney International's Zehnder Practice, of their Australian and co-leader on CEO and Board she focuses where EZI the is appointments in Australia. firm held search privately world's largest in located than 380 consultants with more in 38 countries. 63 wholly owned offices The firm specialises in senior level and consulting board search, executive management appraisals, search, director management.and talent Jane has been at 10 years. for International Egon Zehnder she also holds role her local In addition to in one of leadership role a global strategy after client practices, the Firm's core The Foundation's Board is empowered as the governing body to determine the Foundation's policy the Foundation's and control determine as the governing body to is empowered Board The Foundation's of the Garvan direction Board. subject the ultimate Institute its affairs to Garvan Research Foundation was established in 1981 to provide the Garvan the additional source with an provide Institute in 1981 to established was Foundation Garvan Research and individuals. Over the years, the companies financial support by attracting funds from of research arm. Garvan's and fundraising become communications marketing, to has evolved Foundation Garvan Research Foundation Board Foundation Garvan Research Gabriel Farago Mary Foley Loftus Harris AM

Bill Ferris AC Lyn Gearing Meredith Hellicar

Gabriel Farago Mary Foley Loftus Harris AM Gabriel Farago is a company director and Nominated by the Sisters of Charity Loftus Harris is a non-executive director consultant advising corporations on on boards in NSW, Victoria and Mary Foley held the position of the Chief litigation management. Prior to Queensland, a national director of the Executive Officer, St Vincents & Mater establishing his consultancy, he practised Australian Institute of Export, and holds Health Sydney until early 2008. Ms Foley as a solicitor and barrister for over 30 the appointment of Special Trade is currently the National Health Practice years, specialising in commercial disputes Representative to the Middle East and Leader at PricewaterhouseCoopers. both in Australia and overseas. Mr Farago India for the Queensland Government. Previous positions include Deputy Head, has extensive business interests, and has He previously held chief executive positions NSW Department of Health and Executive been involved in property development in the NSW and Queensland public sectors Director, NSW Office of Health Policy and for more than 20 years. A passion for with responsibility for whole-of- senior executive management positions philanthropic and charitable causes also government activities including international for Mayne Nickless private health care reaches back many years, and in 1984 trade, investment, innovation, business business. Ms Foley is Deputy Chancellor he was made a member of the Knightly and regional development. He also served and a member of the Board of Trustees, Order of Vitez. Mr Farago joined the extensively overseas as an Australian University of Western Sydney as well as Foundation Board in 2008. Trade Commissioner. Mr Harris joined the a member of the Board of Governors of Foundation Board in 2008. Bill Ferris AC University of Notre Dame Australia. Ms Bill Ferris is Executive Chairman of the Foley was NSW Telstra Businesswoman Meredith Hellicar CHAMP Private Equity Group, one of of the Year in 1998 and was awarded the Meredith Hellicar is a company director Australia's leading private capital groups, Centenary Medal in 2003 for service to and consultant in strategy and change. providing venture capital, expansion Australian society in business leadership. She is Chairman of AMP Life and a capital and management buyout funding Ms Foley stepped down from the Boards director of AMP Limited, AMP Bank, in Australasia. Mr Ferris is Chairman of the of the Garvan Institute and Garvan Amalgamated Holdings and the Sydney Garvan Institute of Medical Research and Research Foundation in 2008. Institute. She is a member of the Advisory recently appointed Chair of the Health and Board of the Marsh McLennan Group in Lyn Gearing Hospitals Fund Advisory Board as part of Australia and of the Board of Governors of Lyn Gearing was appointed to the Garvan the Federal Government's Nation-Building CEDA. Meredith was awarded a Centenary Foundation Board in 2005 as a Funds initiative. Former directorships Medal for Business Leadership. Her former representative of the Sisters of Charity. include: Chairman, Australian Trade directorships include James Hardie Ms Gearing was a Director of Stockland Commission (Austrade), Austar United Industries, HLA Envirosciences, Southern Corporation Limited up until December Communications Limited and Bradken Cross Airports Group, NSW Treasury 2008 and is currently a Director of Resources Pty Ltd. Corporation, AurionGold, HCS Limited and Queensland Investment Corporation the NSW Environment Protection Authority. Mr Ferris was made an Officer in the Limited, Hancock Natural Resource Group She was a member of the Takeovers Panel Order of Australia in 1990 for services to Australasia Pty Limited, IMB Limited and and the Foreign Affairs Council and her the export industry and in 2008 was two other not for profit organisations. previous executive roles include Managing made Companion in the Order of Australia Ms Gearing was the CEO of the NSW Director of InTech Financial Services, Chief for his philanthropic activities and his role State Superannuation schemes from Executive Officer of Corrs Chambers in the establishment of the private equity 1997 to 2002, and has substantial Westgarth and Managing Director of TNT sector in Australia. experience in superannuation, funds Logistics Asia. Ms Hellicar joined the management, corporate finance and Foundation Board in 2002. management consulting. Ms Gearing joined the Foundation Board in 2005. I I I I 68 GOVERNANCE IIII 69 GOVERNANCE Brad Rees Brad in a number of is involved Rees Brad arts interests. charitable, and educational a managing director Until 2007, he was and equity partner of the investment banking firm Goldman Sachs JBWere. 23 years and with the firm for was Brad and in the Melbourne, Sydney worked financial and providing offices London corporations to investment banking advice and and governments in Australia joined the Foundation overseas. Mr Rees in 2008. Board Rubic Steven CEO of St appointed was Rubic Steven in April Health Sydney & Mater Vincents Executive this he was to 2008. Prior a Hospital Private Vincent's of St Director 1997. He is position he held since Member of SV&MHS, a Board currently Plan, the Health Industry (Superannuation) a Foundation, the Garvan Research on Commission member of Australian (Private and Quality Health Care Safety and is a past Sector Committee) Hospital Hospitals Chairman of the NSW Private an MBA Association. He has completed Institute of the Australian and is a fellow Directors. of Company Brad Rees Brad Steven Rubic Steven RSC AM RSC AM AM AM John Landerer John Landerer Sister Paulina Pilkington Pilkington Paulina Sister John Landerer John Landerer Sister Paulina has a broad background in background has a broad Paulina Sister having been a health policy formation, and Health member of the Hospitals Services (Sax Commission) Commission Nursing General, and Assistant Director Department of Health. Federal Branch, the Garvan from resigned Paulina Sister 2000 and has in February Board Institute Board been a member of the Foundation 1994. since John Landerer is a solicitor specialising in is a solicitor John Landerer advisory work and is also a corporate He is director. company professional Limited Chairman of Goldsearch currently He has companies. private and other served as Chairman of the Home Authority Assistance and is on Purchase and Australia Education of Life the Board Deaf and Blind for the Royal Institute of as on the Boards as well Children institutions. Mr Landerer various charitable at a Visiting Professor appointed was University in Business and Macquarie Law and holds an honorary Commercial He is also that University. from doctorate Mr University. of Sydney a Fellow of Order is a Member of the Landerer of the Most Commander and a Australia He of the British Empire. Order Excellent of the in the Order is also a Commander Mr Landerer Solidarity. of Italian Star in 2007. joined the Board Pilkington Paulina Sister OAM OAM OAM John Koch Ross King Byram Johnston Johnston Byram Byram Johnston is the Chief Executive Johnston Byram a company of MainstreamBPO, Officer and processing back office providing fund managers services to administration to funds. Prior and superannuation over this business he spent establishing 30 years as a management consultant. He serves of a number of on the board joined the Mr Johnston companies. in 1997. Board Foundation Ross King at Ross King is a Managing Director he has where Goldman Sachs JBWere spent the last 16 years providing investment banking and financing advice. product numerous across He has worked banking, including investment equityareas made a and was sales and research in 1994. He fulfilled senior roles Partner offices and London the New York in both in 2001 as Sydney to returning before & Consumer of the Healthcare, Co-Head Divisions of the Investment Industrial Banking department.has Ross now Resources the Natural for responsibility division. Mr King joined the Foundation down in 2008. in 2005 and stepped Board John Koch of the is Chief Representative John Koch of Group based Forma Hong Kong member of St board a former Companies, and Chair of its Finance Hospital Vincent's Chair of He is also the former Committee. which assists Foundation Cottage Woods intellectually disabled young adults. He had with the Commonwealth a 32 year career and of domestic Bank assuming a range Koch Mr responsibilities. international in 2000. Board joined the Foundation Byram Johnston Johnston Byram John Shine AO FAA The Hon Warwick L Smith AM Peter Wade

Ian Smith Karim Temsamani Richard FE Warburton AO

John Shine AO FAA The Hon Warwick L Smith AM Peter Wade Professor Shine is Executive Director of Warwick Smith is Chairman of the Peter Wade is currently a consultant to a the Garvan Institute of Medical Research, Advisory Board of Australian Capital Equity major financial services organisation and a Professor of Medicine and Professor of group of companies, as well as the ANZ company director. Peter previously spent Molecular Biology at the University of Bank for NSW and the ACT, and of over 25 years providing investment NSW. He is also the recent ex-Chairman E*TRADE Limited. Formerly, Warwick was banking and financial advice with JBWere of the National Health and Medical an Executive Director with Macquarie and its current form, Goldman Sachs Research Council, past president of the Bank. In a 15 year Parliamentary career JBWere; more recently he was with Australian Genome Research Facility, and he served as a Federal Government JPMorgan. He worked for nearly 15 years a past Vice President of the Australian Minister and in a variety of public roles. He in Europe and the United States before Academy of Science. He is an Officer in was Australia's first Telecommunications returning to Australia. He is a Director of the Order of Australia and until 2007 was Ombudsman. Warwick has a strong focus MMC Contrarian Limited, an ASX listed a Member of the Prime Minister's Science, on international affairs. He is Chair of the company. Mr Wade joined the Foundation Engineering and Innovation Council. Global Foundation, Immediate Past Chair Board in 2002 and stepped down in 2008. of the Australia China Business Council Ian Smith Richard FE Warburton AO and Deputy Chair of the Asia Society of Ian Smith was until recently Chief Dick Warburton is currently Chairman of Australia. Mr Smith joined the Foundation Executive of Yahoo!7. He has more than the Board of Taxation, Magellan Flagship Board in 2007 and stepped down in 2008. 20 years experience as a company Fund, and Tandou Limited. He is a director director and advisor in the advertising, Karim Temsamani of Citibank, Chairman of the marketing communications and media Karim Temsamani manages Google's Commonwealth Studies Conference and a industries. Prior to leading the domestic business and strategic Member of the Advisory Council of the management buyout of the partnerships in Australia and New Zealand. Centre for Social Impact. Mr Warburton is Communications Group in 2003, Mr Karim joined Google from Fairfax Media, a former Chairman and CEO of DuPont Smith spent five years in New York as where he was most recently Group Australia and New Zealand, whom he had President International of Bates Director, Fairfax General Magazines worked with for 30 years. Mr Warburton Worldwide and Director of the publicly (responsible for growing the profile and joined the Foundation Board in 1999 and listed Cordiant Communications PLC. He advertising revenue of Fairfax's suite of stepped down in 2008. also led the development of Cordiant's inserted magazines) and Commercial global e-business consultancy, which Director for Newspapers (responsible for now operates in most major markets agency and group sales, trade marketing around the world. Mr Smith has served and business development). Prior to this on a number of government and he was the publisher and Vice President of philanthropic advisory groups including Who Weekly at Time Inc South Pacific. He the Whitney Museum in New York and has previously served in a variety of senior the State Library of New South Wales. capacities with Hachette, including the Mr Smith joined the Foundation Board in positions of regional business publisher in 2005 and stepped down in 2008. Hong Kong, associate publisher for Korea in Seoul, and managing director for Hachette in Sydney. Mr Temsamani joined the Foundation Board in 2008. I I I I 70 GOVERNANCE

I I I I I I I I I PUBLICATIONS

Abdipranoto A, Wu S, Stayte S, Vissel B. Avery DT, Ma CS, Bryant VL, Santner- Boey D, Lin S, Enriquez RF, Lee NJ, Slack K, The role of neurogenesis in Nanan B, Nanan R, Wong M, Fulcher DA, Couzens M, Baldock PA, Herzog H, neurodegenerative diseases and its Cook MC, Tangye SG. STAT3 is required Sainsbury A. PYY transgenic mice are implications for therapeutic development. for IL-21-induced secretion of IgE from protected against diet-induced and CNS Neurol Disord Drug Targets 2008; human naive B cells. Blood 2008; genetic obesity. Neuropeptides 2008; 7:187-210. 112:1784-93. 42:19-30. Achuthan A, Masendycz P, Lopez JA, Bao Y, Lopez JA, James DE, Hunziker W. Bogaerts S, Douglas S, Corlette T, Pau H, Nguyen T, James DE, Sweet MJ, Hamilton Snapin Interacts with the Exo70 Subunit Saunders D, McKay S, Oleskevich S. JA, Scholz GM. Regulation of the of the Exocyst and Modulates GLUT4 Microsurgical access for cell injection into endosomal SNARE protein syntaxin 7 by Trafficking. J Biol Chem 2008; 283:324-31. the mammalian cochlea. J Neurosci Methods 2008; 168:156-63. colony-stimulating factor 1 in Barton CA, Clark SJ, Hacker NF, O'Brien macrophages. Mol Cell Biol 2008; PM. Epigenetic markers of ovarian cancer. Bolton K, Segal D, McMillan J, Jowett J, 28:6149-59. Adv Exp Med Biol 2008; 622:35-51. Heilbronn L, Abberton K, Zimmet P, Chisholm D, Collier G, Walder K. Decorin is Ahlborg HG, Nguyen ND, Center JR, Barton CA, Hacker NF, Clark SJ, O'Brien a secreted protein associated with obesity Eisman JA, Nguyen TV. Incidence and risk PM. DNA methylation changes in ovarian and type 2 diabetes. Int J Obes (Lond) factors for low trauma fractures in men cancer: implications for early diagnosis, 2008; 32:1113-21. with prostate cancer. Bone 2008; prognosis and treatment. Gynecol Oncol 43:556-60. 2008; 109:129-39. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, Dobles M, Scott ML, Maquelin Akerfeldt MC, Howes J, Chan JY, Stevens Basten A. The evolution of clinical A, Belnoue E, Siegrist CA, Chevrier S, VA, Boubenna N, McGuire HM, King C, immunology and allergy in Australia. Acha-Orbea H, Leung H, Mackay F, Biden TJ, Laybutt DR. Cytokine-induced Immunol Cell Biol 2008; 86:16-21. beta-cell death is independent of Tschopp J, Schneider P. TACI, unlike BAFF- endoplasmic reticulum stress signaling. Basten A, Fazekas de St Groth B. Special R, is solely activated by oligomeric BAFF Diabetes 2008; 57:3034-44. regulatory T-cell review: T-cell dependent and APRIL to support survival of activated suppression revisited. Immunology 2008; B cells and plasmablasts. Blood 2008; American Association for Cancer Research 123:33-9. 111:1004-12. Human Epigenome Task Force; European Union, Network of Excellence, Scientific Bennett HL, Brummer T, Jeanes A, Yap Boyman O, Ramsey C, Kim DM, Sprent J, Advisory Board. Moving AHEAD with an AS, Daly RJ. Gab2 and Src co-operate in Surh CD. IL-7/anti-IL-7 mAb complexes international human epigenome project. human mammary epithelial cells to restore T cell development and induce Nature 2008; 454:711-5. promote growth factor independence homeostatic T Cell expansion without and disruption of acinar morphogenesis. lymphopenia. J Immunol 2008; Anton SD, Martin CK, Redman L, York- Oncogene 2008; 27:2693-704. 180:7265-75. Crowe E, Heilbronn LK, Han H, Williamson DA, Ravussin E. Psychosocial and Biankin AV, Nguyen NQ, Merrett ND. Post- Bradbury RA, Samaras K. Antiretroviral behavioral pre-treatment predictors of pancreatectomy management. Medical therapy and the human immunodeficiency weight loss outcomes. Eat Weight Disord Observer 2008:27-29. virus--improved survival but at what cost? Diabetes Obes Metab 2008; 2008; 13:30-7. Biden TJ, Schmitz-Peiffer C, Burchfield JG, 10:441-50. Avery DT, Bryant VL, Ma CS, de Waal Gurisik E, Cantley J, Mitchell CJ, Carpenter Malefyt R, Tangye SG. IL-21-induced L. The diverse roles of protein kinase C in Brink R, Phan TG, Paus D, Chan TD. isotype switching to IgG and IgA by pancreatic beta-cell function. Biochem Visualizing the effects of antigen affinity human naive B cells is differentially Soc Trans 2008; 36:916-9. on T-dependent B-cell differentiation. regulated by IL-4. J Immunol 2008; Immunol Cell Biol 2008; 86:31-9. 181:1767-79. I I I I 72 PUBLICATIONS IIII 73 J 2008; Behav J Rheumatol Med J Aust Med Psychiatr Genet Nature PUBLICATIONS 2008; 99:341-9. Nat Clin Pract 2008; 4:198-9. 2008; 5:249-57. 2008; 149:154-60. 2008; 8:104. 2008; 105:641-52. 2008; 122:748-59. Schizophr Res Schizophr Danaher RN, Loomes KM, Leonard BL, KM, Leonard RN, Loomes Danaher EW, Kraegen L,Whiting DL, Hay LY, Xu AR,Phillips that GJ. Evidence Cooper Is Peptide Gene-Related {alpha}-Calcitonin Systemic Controls that a Neurohormone Utilization. and Lipid Availability Endocrinology ND. Merrett Das A, Biankin AV, Chang D, human following Pancreatitis papillomavirus vaccination. 2008; 189:178. Dean B, Karl T, Pavey G, Boer S, Duffy Pavey L,Dean B, Karl T, 2A E. serotonin levels of Scarr Increased in the transporter and serotonin receptors 1 hypomorphic/mutant CNS of neuregulin mice. SG. Immunology:Deenick EK, Tangye sticky. are Helpful T cells 2008; 18:226-39. Martinez-Arias AM, Robertson H, Eid JP, Hime GR, Dziadek M. The Drosophila in cell orthologue,STIM1 has roles dSTIM, and tissue patterning. specification fate Dev Biol BMC and prevention Eisman JA. Osteoporosis in elderly men--a cost- treatment effective strategy. Endocrinol Metab Eisman JA, R, Civitelli Adami S, Czerwinski E, Zaidi C, R, Recknor JY, Prince Reginster Hughes C, N, D, Mairon M, Felsenberg DM, Delmas PD, Reid D, Masanauskaite RR. Efficacy of and tolerability Recker injections in ibandronate intravenous 2-year postmenopausal osteoporosis: study. the DIVA from results 2008; 35:488-97. 455:745-7. Duffy HortDoyle KL, Y, L, Karl T, Shine J, the for critical are receptors H. Y1 Herzog cells of adult mouse precursor proliferation neuroepithelium. in the olfactory Neurosci PA. Silveira AG, Baxter FD, Dufour B-lymphocytes and between Interactions type diabetes. 1 NKT in autoimmune cells J Immunotoxicol Schofield PR. CE,Duncan AF, Chetcuti brain of genes in the mouse Coregulation with clozapine, treatment following implicates haloperidol, or olanzapine subunit channel potassium altered in the mechanism of expression drug action.antipsychotic Neurochem Duffy L, Cappas E, Scimone A, Schofield of a profile Behavioral PR, Karl T. model for mouse mutant heterozygous 1. domain neuregulin EGF-like 2008; 2008; Nat Rev 2008; 2008; 52:613-22. Cancer J Gastroenterol 2008; 1:ra5. Psychiatr Genet J Gastroenterol Hepatol J Gastroenterol Am J Hypertens 2008; 112:672-9. Protein Eng Des Sel Protein J Allergy Clin Immunol J Allergy Sci Signal Blood 2008; 23:1036-45. 2008; 8:535-45. Histopathology Chang DK, Merrett ND, Biankin AV. Chang DK, ND, Merrett operable for outcomes Improving safer to cancer: is access pancreatic the problem? surgery A,Chetcuti Adams LJ, PB, Mitchell gene expression Schofield PR. Microarray mRNA in a model of mouse brain profiling of lithium treatment. 2008; 18:64-72. Engineering Escherichia Chin JW. D, Christ by synthetic gene heat-resistance coli amplification. 21:851. Hepatol 21:121-5. E, N, Rolph MS, Clarke Page Rahman N, GJ, Jones GJ. Functional Stewart of the atopy-associated characterization gene PHF11. 113:135-42. DR,Croucher S, Saunders DN, Lobov roles the biological Ranson M. Revisiting in cancer. (SERPINB2) of PAI2 2008; 121:1148-1154 e3. EK,Colvin Kench DK, Chang ND, Merrett for Individualizing therapy JG, Biankin AV. cancer. pancreatic 2008; 23:1779-82. MR, Kohonen-Corish Chan C, WA, Cooper C, McCaughan B, Kennedy Kwun SY, Sutherland RL, CS. Prognostic Lee MLH1, proteins of DNA repair significance in non- expression MSH2 and MGMT and precursor lung cancer small-cell lesions. MR, Kohonen-Corish Zhuang WA, Cooper L, G, C, McCaughan B, Kennedy Screaton Sutherland RL, prognostic CS. Role and Lee factor- of tumor necrosis significance ligand death apoptosis-inducing related lung cancer DR5 in nonsmall-cell receptor lesions. and precursor Cancer JR, ME. S, Greenfield Safar Czernichow Impact of abdominal adiposity on disease predictors: what is cardiovascular the missing link? Chaganti S, Ma CS, Bell AI, Croom-Carter Chaganti S, Rickinson AB. SG, Tangye AD, Hislop D, in the virus persistence Epstein-Barr memory B cells: of conventional absence virus harbor the cells IgM+IgD+CD27+ B disease lymphoproliferative in X-linked patients. Cao XR,Croucher Lill NL, PP, N, Shi Boase T, EM, Place DR, J, Sweezer Shan H, Qu B. Nedd4 RJ, Daly S, Yang Kumar PA, Kirby IGF- by regulating growth animal controls 1 signaling. 2008; Oncogene 2008; Growth Adv Exp Med Int J Obes Cancer Res Cancer Breast Cancer Res Cancer Breast J Clin Endocrinol Metab 2008; 18:55-64. Breast Cancer Online Cancer Breast 2008; 9:101-10. 2008; 27:2305-2316. 2008; 32:723-4; author reply 2008; 630:189-205. Brummer T, Larance M, Abreu MT, Lyons MT, Abreu M, Larance T, Brummer ED, Fleuren CH, Emmerich RJ,P, Timpson M, Guilhaus D, GM, Schramek Lehrbach James DE, RJ. Daly Phosphorylation- terminates binding of 14-3-3 dependent protein. the Gab2 docking signalling by Embo J Burt Gibney J, Hoffman MG, DM, Umpleby AM, Ho KK. GH- between Relationship and changes in changes metabolic induced and time course a dose body composition: adults. in GH-deficient study Horm IGF Res Burt AM, Johannsson G, Umpleby MG, Ho KK. ImpactChisholm DJ, of growth on hormone and dehydroepiandrosterone in glucocorticoid- metabolism protein patients. treated 2008; 93:688-95. and TRAIL Butt AJ. of "Tamoxifen Review in breast apoptosis induce synergistically cells." cancer 11:e4. Butt AJ,Caldon CE, McNeil CM, Swarbrick A, EA, Musgrove Sutherland RL. cycle Cell machinery: links with genesis and cancer. of breast treatment Biol Butt AJ, CM, Inman CK, Sergio Anderson LR, AJ, McNeil CM, Russell M, Nousch RL, Sutherland Biankin AV, T, Preiss EA. and c-Myc Musgrove The estrogen is over-expressed gene HSPC111 target with poor and associated cancer in breast patient outcome. 2008; 10:R28. Caldon CE, CS, Sutherland RL, Lee 1: an EA.Musgrove Wilms' tumor protein in T- regulation of progestin early target that modulates cells cancer 47D breast and differentiation. proliferation 2008; 27:126-38. Caldon CE, A, CS, Swarbrick Lee Sutherland RL, EA. Musgrove The helix- cyclin D1 Id1 requires loop-helix protein of mammary the proliferation promote to acini. epithelial cell 68:3026-36. H, Wand Calmy Mallon PW, A, D, Carey DA,Law M, Cooper Carr A. changes Early in adipokine levels and baseline limb fat over 2 years HIV lipoatrophy may predict therapy. initiation of antiretroviral following HIV Med The thrifty gene hypothesis: Campbell LV. maybe everyone is right? (Lond) 725-6. Elder GJ. Nephrotic syndrome: don't forget Guerrero-Bosagna CM, Sabat P, Hoehn KL, Hohnen-Behrens C, Cederberg the bones! Nephrology (Carlton) 2008; Valdovinos FS, Valladares LE, Clark SJ. A, Wu LE, Turner N, Yuasa T, Ebina Y, 13:43-4. Epigenetic and phenotypic changes result James DE. IRS1-independent defects from a continuous pre and post natal define major nodes of insulin resistance. Famm K, Hansen L, Christ D, Winter G. dietary exposure to phytoestrogens in an Cell Metab 2008; 7:421-33. Thermodynamically stable aggregation- experimental population of mice. BMC resistant antibody domains through Hokfelt T, Stanic D, Sanford SD, Gatlin JC, Physiol 2008; 8:17. directed evolution. J Mol Biol 2008; Nilsson I, Paratcha G, Ledda F, Fetissov S, 376:926-31. Harmer AR, Chisholm DJ, McKenna MJ, Lindfors C, Herzog H, Johansen JE, Ubink Hunter SK, Ruell PA, Naylor JM, Maxwell R, Pfenninger KH. NPY and its Frangioudakis G, Cooney GJ. Acute LJ, Flack JR. Sprint training increases muscle involvement in axon guidance, elevation of circulating fatty acids impairs oxidative metabolism during high-intensity neurogenesis, and feeding. Nutrition downstream insulin signalling in rat skeletal exercise in patients with type 1 diabetes. 2008; 24:860-8. muscle in vivo independent of effects on Diabetes Care 2008; 31:2097-102. stress signalling. J Endocrinol 2008; Hoy AJ, Turner N. New insight into the 197:277-85. Heilbronn LK, Campbell LV. Adipose tissue mechanism by which acute physical macrophages, low grade inflammation and exercise ameliorates insulin resistance. Gardam S, Sierro F, Basten A, Mackay F, insulin resistance in human obesity. Curr J Physiol 2008; 586:2251-2. Brink R. TRAF2 and TRAF3 signal adapters Pharm Design 2008; 14:1225-30. act cooperatively to control the Hubert FX, Kinkel SA, Webster KE, Cannon maturation and survival signals delivered Heiser PW, Cano DA, Landsman L, Kim GE, P, Crewther PE, Proeitto AI, Wu L, Heath to B cells by the BAFF receptor. Immunity Kench JG, Klimstra DS, Taketo MM, Biankin WR, Scott HS. A specific anti-Aire 2008; 28:391-401. AV, Hebrok M. Stabilization of beta- antibody reveals aire expression is catenin induces pancreas tumor formation. restricted to medullary thymic epithelial Gatt JM, Kuan SA, Dobson-Stone C, Paul Gastroenterology 2008; 135:1288-300. cells and not expressed in periphery. RH, Joffe RT, Kemp AH, Gordon E, J Immunol 2008; 180:3824-32. Schofield PR, Williams LM. Association Hill NJ, King C, Flodstrom-Tullberg M. between BDNF Val66Met polymorphism Recent acquisitions on the genetic basis of Karl T, Duffy L, Herzog H. Behavioural and trait depression is mediated via resting autoimmune disease. Front Biosci 2008; profile of a new mouse model for NPY EEG alpha band activity. Biol Psychol 13:4838-51. deficiency. Eur J Neurosci 2008; 2008; 79:275-84. 28:173-80. Hilton HN, Stanford PM, Harris J, Oakes Govers R, James DE, Coster AC. High- SR, Kaplan W, Daly RJ, Ormandy CJ. KIBRA Karlstrom H, Brooks WS, Kwok JB, Broe throughput analysis of the dynamics of interacts with discoidin domain receptor 1 GA, Kril JJ, McCann H, Halliday GM, recycling cell surface proteins. Methods to modulate collagen-induced signalling. Schofield PR. Variable phenotype of Mol Biol 2008; 440:129-46. Biochim Biophys Acta - Mol Cell Res Alzheimer's disease with spastic 2008; 1783:383-93. paraparesis. J Neurochem 2008; Greenfield JR, Campbell LV. Role of the 104:573-83. autonomic nervous system and Hinshelwood RA, Clark SJ. Breast cancer neuropeptides in the development of epigenetics: normal human mammary Katsoulotos GP, Qi M, Qi JC, Tanaka K, obesity in humans: targets for therapy? epithelial cells as a model system. J Mol Hughes WE, Molloy TJ, Adachi R, Stevens Curr Pharm Des 2008; 14:1815-20. Med 2008; 86:1315-28. RL, Krilis SA. The Diacylglycerol- dependent translocation of ras guanine Greenfield JR, Moore J, Hill D, Brenner P, Ho KK. Can a single growth hormone level nucleotide-releasing protein 4 inside a Delprado W, Turner J, Taylor J, Campbell L, be used to assess disease activity after human mast cell line results in substantial Wong LY. Cushing's syndrome can treatment of acromegaly? Nat Clin Pract phenotypic changes, including expression precipitate diabetes but mask non- Endocrinol Metab 2008; 4:74-5. of interleukin 13 receptor alpha2. J Biol Hodgkin's lymphoma. Med J Aust 2008; Ho KKY. Effect of gonadal steroids on Chem 2008; 283:1610-21. 188:262. growth hormone action. In: Web SM, Kebede M, Favaloro J, Gunton JE, Laybutt Grey ST. Regulating inflammation: The ying Chanson P, editors. A Decade of HypoCCS: DR, Shaw M, Wong N, Fam BC, Aston- and yang of NF-kappaB activation. The Changing Face of Pituitary Disease. Mourney K, Rantzau C, Zulli A, Proietto J, Immunol Cell Biol 2008; 86:299-300. Bristol UK: BioScientifica LTD; 2008. p. Andrikopoulos S. Fructose-1,6- 129-142. Groom J, Mackay F. B cells flying solo. bisphosphatase overexpression in Immunol Cell Biol 2008; 86:40-6. Ho LL, Kench JG, Handelsman DJ, Scheffer pancreatic beta-cells results in reduced GL, Stricker PD, Grygiel JG, Sutherland RL, insulin secretion: a new mechanism for Grunfeld C, Kotler DP, Arnett DK, Falutz Henshall SM, Allen JD, Horvath LG. fat-induced impairment of beta-cell JM, Haffner SM, Hruz P, Masur H, Meigs Androgen regulation of multidrug function. Diabetes 2008; 57:1887-95. JB, Mulligan K, Reiss P, Samaras K. resistance-associated protein 4 Contribution of metabolic and Kench JG, Cosman PH, Merrett ND, (MRP4/ABCC4) in prostate cancer. anthropometric abnormalities to Biankin AV. Pathology and molecular Prostate 2008; 68:1421-9. cardiovascular disease risk factors. biology of intraductal papillary mucinous Circulation 2008; 118:e20-8. Hocking SL, Chisholm DJ, James DE. neoplasms. In: Lowy AM, Leach SD, Philip Studies of regional adipose transplantation PA, editors. Pancreatic Cancer. New York: reveal a unique and beneficial interaction Springer Verlag; 2008. p. 63-64. between subcutaneous adipose tissue and the intra-abdominal compartment. Diabetologia 2008; 51:900-2. I I I I 74 PUBLICATIONS IIII 75 Thromb 2008; 8:32. J Biol Chem PUBLICATIONS 2008; 19:17-29. BMC Neurol BMC 2008; 25:1142-50. Mol Biol Cell Mol 2008; 100:319-29. 2008; 57:2728-36. Llado A, Timpson P, Vila de Muga S, Llado A, P, Timpson Daly RJ, Enrich T, A, J, Pol Grewal Moreto and Kinase C{delta} Protein F. C, Tebar Epidermal Growth Calmodulin Regulate Early Recycling from Receptor Factor and Complex Arp2/3 Endosomes through Cortactin. Lloret-Linares C, JR, Greenfield Lloret-Linares S. Effect of weight-reducing Czernichow and parameters agents on glycaemic 2 diabetes: a review. Type to progression Med Diabet DR, S, Croucher Lobov Saunders DN, Ranson M. Plasminogen activator inhibitor associated surface type 2 inhibits cell tissue plasminogen activator in vitro: interactions. receptor potential Haemost Xie L, James DE, JA,Lopez He Y, EP, Kwan Is a Central The RalA GTPase Gaisano HY. of Insulin Exocytosis from Regulator Cells. Beta Islet Pancreatic 2008; 283:17939-45. Roggli E, Laybutt DR,Lovis P, S, Gattesco Widmann C, A, JY, Abderrahmani Yang in microRNA Alterations R. Regazzi acid- fatty to contribute expression dysfunction. beta-cell pancreatic induced Diabetes Luty AA, JB, Thompson EM, Kwok Dobson- WS, Loy CT, Brooks P, Blumbergs C, PK,Stone Panegyres J, Hecker Nicholson GA, Halliday GM, Schofield PR. lobar with frontotemporal Pedigree disease and neuron degeneration--motor positive DNA binding protein-43 Tar neuropathology: linkage to genetic 9. chromosome Curr 2008; 2008; 31:e13. Obesity (Silver 2008; 189:336-7. Arch Intern Med Intern Arch 2008; 135:1870-6. 2008; 6:62-6. Diabetes Care Diabetes 2008; 24:892-9. Diabetes Care Diabetes Bone Marrow Transplant Bone Marrow Med J Aust Med 2008; 16:356-62. Nutrition Lee P, Greenfield JR, Campbell LV. "Mind JR, Greenfield Campbell LV. P, Lee in the gap" when managing ketoacidosis type 1 diabetes. 31:e58. Jones GR, JR. Successful Center P, Lee salt wasting cerebral of adult treatment with fludrocortisone. 2008; 168:325-6. JR. S, Center Milliken P, Lee post BMT failure cardiac Hypocalcaemic D vitamin unrecognized to secondary deficiency. 2008; 42:363-4. K. Samaras disease in an Coeliac P, Lee Indian patient: diagnosis to an important consider. Leong RW, Nguyen NQ, Meredith CG, Al- Nguyen NQ, CG, RW, Meredith Leong ER, Murr Delaney PM, D, Sohaily S, Kukic In vivo Biankin AV. ND, J, Merrett Yong in the diagnosis endomicroscopy confocal disease. and evaluation of celiac Gastroenterology AM, LK, Poynten Li H, Heilbronn Hu D, Kaplan Blackburn MA, Shirkhedkar DP, Islet- J, Chisholm DJ. Ye AD, WH, Kriketos an islet for role important 1: a potentially fat. gene in visceral cell Spring) Lee P, Campbell LV. Diabetic ketoacidosis: Diabetic Campbell LV. P, Lee A novel the usual villain or a scapegoat? acidosis in type metabolic of severe cause 1 diabetes. Lee NJ, Enriquez RF, Boey D, Lin S, Slack K, Boey D, RF, NJ, Enriquez Lee H, Sainsbury A.Herzog Baldock PA, of obesity by Y2- attenuation Synergistic in ob/ob double knockout and Y4-receptor mice. Rep Osteoporos Lee NJ, Wong IP, Baldock PA, Herzog H. Herzog Baldock PA, IP, NJ, Wong Lee as an endocrine signal in bone. Leptin Curr 2008; 2008; 2008; 2008; Ann Neurol 2008; 26:741-66. 2008; 86:153-60. Mol Endocrinol Mol Proc Natl Acad Sci U S A Natl Acad Proc 2008; 19:235-41. Immunol Cell Biol Immunol Cell Obesity Spring) (Silver King C. T helper cell differentiation: IL-21 King C. differentiation: T helper cell Jack of differentiation: and T helper cell all trades? 86:554-6. CR. T SG, Mackay King C, Tangye Helper (T(FH))Follicular in Normal Cells Responses. Immune and Dysregulated Immunol Annu Rev acids fatty GJ. Free Cooney EW, Kraegen muscle insulin resistance. and skeletal Opin Lipidol N. Muscle GJ, Turner Cooney EW, Kraegen of fat a case insulin resistance: mitochondrial not overconsumption, dysfunction. 2008; 105:7627-8. G, Lau E, Hamilton CT, JB, Loy Kwok GA, MJ, Broe Hallupp M, Williams J, Owen S, Lovestone JF, N, Lam L, Powell Tang synthase kinase- Schofield PR. Glycogen in genes interact and tau 3beta Alzheimer's disease. 16:1355-62. PL, H, Whitfeld Lee Receptors Mackay CR. of C5a. The importance complement for of C5L2. C5aR and the enigmatic role Biol Immunol Cell 64:446-54. M, Ramm G, James DE. The Larance Code. GLUT4 22:226-33. Larson-Meyer DE, BR, Newcomer J, Smith SR, LK,Heilbronn Volaufova M, Rood JC, AJ,Alfonso Lefevre Williamson DA, Ravussin E. Effect of 6- on and exercise restriction month calorie of liver serum and liver lipids and markers function. Ma CS, Chew GY, Simpson N, Priyadarshi Marino E, Grey ST. A new role for an old Nelson AE, Ho KK. A robust test for A, Wong M, Grimbacher B, Fulcher DA, player: do B cells unleash the self-reactive growth hormone doping--present status Tangye SG, Cook MC. Deficiency of Th17 CD8+ T cell storm necessary for the and future prospects. Asian J Androl cells in hyper IgE syndrome due to development of type 1 diabetes? J 2008; 10:416-25. mutations in STAT3. J Exp Med 2008; Autoimmun 2008; 31:301-5. Nelson AE, Meinhardt U, Hansen JL, 205:1551-7. Meier C, Nguyen TV, Handelsman DJ, Walker IH, Stone G, Howe CJ, Leung KC, MacArthur DG, Seto JT, Chan S, Quinlan Schindler C, Kushnir MM, Rockwood AL, Seibel MJ, Baxter RC, Handelsman DJ, KG, Raftery JM, Turner N, Nicholson MD, Meikle AW, Center JR, Eisman JA, Seibel Kazlauskas R, Ho KK. Pharmacodynamics Kee AJ, Hardeman EC, Gunning PW, MJ. Endogenous sex hormones and of growth hormone abuse biomarkers and Cooney GJ, Head SI, Yang N, North KN. incident fracture risk in older men: the the influence of gender and testosterone: An Actn3 knockout mouse provides dubbo osteoporosis epidemiology study. a randomized double-blind placebo- mechanistic insights into the association Arch Intern Med 2008; 168:47-54. controlled study in young recreational between alpha-actinin-3 deficiency and athletes. J Clin Endocrinol Metab 2008; Merrett ND, Cosman P, Biankin AV. human athletic performance. Hum Mol 93:2213-22. Education of imaging. Hepatobiliary and Genet 2008; 17:1076-86. pancreatic: iatrogenic hemobilia. J Ng Y, Ramm G, Lopez JA, James DE. Rapid Mackay CR. Moving targets: cell migration Gastroenterol Hepatol 2008; 23:821. activation of Akt2 is sufficient to inhibitors as new anti-inflammatory stimulate GLUT4 translocation in 3T3-L1 Murphy NC, Scarlett CJ, Kench JG, Sum therapies. Nat Immunol 2008; 9:988-98. adipocytes. Cell Metab 2008; 7:348-56. EY, Segara D, Colvin EK, Susanto J, Mackay F, Schneider P. TACI, an enigmatic Cosman PH, Lee CS, Musgrove EA, Nguyen ND, Frost SA, Center JR, Eisman BAFF/APRIL receptor, with new Sutherland RL, Lindeman GJ, Henshall SM, JA, Nguyen TV. Development of unappreciated biochemical and biological Visvader JE, Biankin AV. Expression of prognostic nomograms for individualizing properties. Cytokine Growth Factor Rev LMO4 and outcome in pancreatic ductal 5-year and 10-year fracture risks. 2008; 19:263-76. adenocarcinoma. Br J Cancer 2008; Osteoporos Int 2008; 19:1431-44. 98:537-541. Mallon PW, Sedwell R, Rogers G, Nolan D, Nguyen NK, Sartori SB, Herzog H, Tasan R, Unemori P, Hoy J, Samaras K, Kelleher A, Musgrove EA, Sergio CM, Anderson LR, Sperk G, Singewald N. Effect of Emery S, Cooper DA, Carr A. Effect of Inman CK, McNeil CM, Alles MC, neuropeptide Y Y2 receptor deletion on Rosiglitazone on Peroxisome Proliferator- Gardiner-Garden M, Ormandy CJ, Butt AJ, emotional stress-induced neuronal Activated Receptor gamma Gene Sutherland RL. Identification of activation in mice. Synapse 2008; Expression in Human Adipose Tissue Is downstream targets of estrogen and c- 63:236-246. Limited by Antiretroviral Drug-Induced myc in breast cancer cells. Adv Exp Med Nguyen TV, Center JR, Eisman JA. Mitochondrial Dysfunction. J Infect Dis Biol 2008; 617:445-51. Pharmacogenetics of osteoporosis and 2008; 198:1794-1803. Musgrove EA, Sergio CM, Loi S, Inman CK, the prospect of individualized prognosis Marino E, Batten M, Groom J, Walters S, Anderson LR, Alles MC, Pinese M, Caldon and individualized therapy. Curr Opin Liuwantara D, Mackay F, Grey ST. CE, Schutte J, Gardiner-Garden M, Endocrinol Diabetes Obes 2008; Marginal-zone B-cells of nonobese Ormandy CJ, McArthur G, Butt AJ, 15:481-8. diabetic mice expand with diabetes onset, Sutherland RL. Identification of functional invade the pancreatic lymph nodes, and networks of estrogen- and c-Myc- present autoantigen to diabetogenic T- responsive genes and their relationship to cells. Diabetes 2008; 57:395-404. response to tamoxifen therapy in breast cancer. PLoS ONE 2008; 3:e2987. I I I I 76 PUBLICATIONS IIII 2008; 2008; 77 2008; 2008; 2008; 2008; Eur J Immunol Eur PUBLICATIONS ANZ J Surg ANZ 2008; 57:1774-83. Immunol Cell Biol Immunol Cell J Bone Miner Res Immunol Cell Biol Immunol Cell 2008; 99:375-82. Diabetes 2008; 101:492-6. Expert Rev Mol Med Expert Rev Proc Natl Acad Sci U S A Sci Natl Acad Proc 10:e15. N, Carter K,Sims AM, Shephard Doan T, Dowling A, EL, Duncan Eisman J, Jones G, R,Nicholson G, Prince Seeman E, Thomas JA, MA. Brown analyses Genetic G, Wass in a sample of individuals with high or low BMD shows association with multiple Wnt genes. pathway 23:499-506. I, Kisielow J, Meier R,Sonderegger King C, not are and IL-21R M. IL-21 Kopf development of Th17 cells for required in vivo. and autoimmunity 2008; 38:1833-8. J, Cho JH. Self/non-self Sprent of keeping discrimination and the problem alive. T cells inflammation - lessons from studies in the studies inflammation - lessons from mouse. 86:54-6. T Surh CD. J, Cho JH, Boyman O, Sprent homeostasis. cell 105:10883-8. kinase Protein C,Schmitz-Peiffer Biden TJ. beta-cells and C function liver, in muscle, type 2 for implications and its therapeutic diabetes. CS, Lee WA, Cooper N, Currey Seng TJ, Chan C, Horvath L, Sutherland RL, C,Kennedy McCaughan B, Kohonen- and MLH1 promoter MR. DLEC1 Corish with poor associated are methylation lung carcinoma. in non-small cell prognosis Br J Cancer AA, Tesoriero Severi G, Hayes VM, Southey MC, EJ, Morris Hoang HN, Padilla HA, English DR, Sutherland RL, Boyle P, Hopper JL, Giles GG. The rs743572 of variant in the promoter common with prostate associated CYP17A1 is not hormonal levels. risk or circulating cancer Int BJU WA. Sewell Rolph MS, Shum BO, airway Mechanisms in allergic 86:312-9. Samra JS, Biankin AV, Merrett ND. Role of ND. Merrett AV, JS, Biankin Samra management in the ultrasound endoscopic lesions. of pancreatic 316-7. author reply 78:315-6; Derudder E, Calado Zhang B, DP, Sasaki Y, S, Nishikawa F, Mackay Shimizu Y, Rajewsky K, M. NIK Schmidt-Supprian ablation whereas amplifies, overexpression of its TRAF3-binding domain replaces survivalBAFF:BAFF-R-mediated signals in B cells. J 2008; 2008; 2008; BMC Nat Med Cancer Epidemiol Cancer 2008; 61:238-45. 2008; 180:5320-6. Cancer Epidemiol Cancer 2008; 180:6508-17. 2008; 17:3615-7. 2008; 17:2488-97. J Appl Physiol 2008; 9:197. J Immunol J Immunol Pedersen DJ, Lessard SJ, Coffey VG, SJ, Coffey Lessard DJ, Pedersen Watt T, AM, Ng EG, Wootton Churchley MJ, Hawley JA. muscle of rates High exhaustive after resynthesis glycogen is coingested when carbohydrate exercise with caffeine. 105:7-13. DC, HN, Padilla Severi G, Hoang Petersen EJ, Southey MC, English DR,JL, Hopper No association Giles GG, Hayes VM. chemokine and common between gene variants and chemokine receptor risk. cancer prostate Prev Biomarkers E,Polkinghorne Lau Q, GJ, Cooney ME. Cleasby activation EW, Local Kraegen in pathway of the I{kappa}K-NF-{kappa}B insulin resistance. cause muscle does not Am J Physiol Metab Endocrinol 294:E316-E325. Martin IC,Ramanathan P, Gardiner- RM, M, Thomson PC,Garden Taylor Ormandy CJ, C, Moran Williamson P. analysis identifies pathways Transcriptome maternal with enhanced associated in QSi5 mice. performance Kim DM, Cho Ramsey C, MP, Rubinstein The lymphopenic J, Surh CD. JH, Sprent of CD132 (common environment elicits rapid gamma-chain)-deficient hosts of naive T cells proliferation homeostatic via IL-15. Genomics Samaras K. Metabolic consequences and K.Samaras consequences Metabolic options in highly active therapeutic in human therapy antiretroviral immunodeficiency virus-1 infection. Chemother Antimicrob 14:551-7. SG, Tangye DT, Avery Rosen DB, Cao W, Lanier LL. Functional Houchins JP, Liu YJ, between of interactions consequences human NKR-P1A and its ligand LLT1 and on activated dendritic cells expressed B cells. AJ,Sakko BJ, Butler MS, Byers S, Reinboth Sutherland JG, Horvath J, Kench LG, Stahl Henshall SM, Marshall VR,RL, PD, Stricker C. Ricciardelli DJ, Horsfall WD, Tilley level of unsulfated Immunohistochemical in the cancer disaccharides chondroitin of is an independent predictor stroma relapse. cancer prostate Prev Biomarkers Rittirsch D, Flierl MA,Rittirsch D, Nadeau BA, Day DE, M, Mackay CR, FS, Huber-Lang Zetoune C, Cianflone K, J, Gerard Kohl NP, Gerard for Functional roles PA. Ward Sarma JV, in sepsis. C5a receptors 2008; 2008. Current Genes Brain 2008; 55:117-26. 2008; 54:1268-76. 2008; 112:3293-302. J Mammary Biol Gland 2008; 98:1085-93. 2008; 22:581-6. Rheumatology (Oxford) 2008; 13:13-28. Blood 2008; 7:532-42. Clin Chem Ormandy CJ. Prolactin Receptor. Ormandy CJ. Receptor. Prolactin Nguyen TV, Nelson AE, TV, Nguyen CJ, Howe Seibel Kazlauskas RC,MJ, Baxter DJ, Handelsman R, KK. Ho Within-subject variability and growth of insulinlike analytic imprecision markers: collagen axis and factor diagnosis and doping clinical for implications tests. Mackay D, Nossent JC, S, Zahra Lester CR, the in Rischmueller M. Polymorphism of the B-lymphocyte region 5' regulatory with activating gene is associated factor and the Ro/La response autoantibody primaryserum BAFF levels in Sjogren's syndrome. 47:1311-6. Smith Davies MJ, Scurry JP, O'Brien PM, CA,AN, Barton Henderson MJ, Saunders KI, Clancy JL, Patterson DN, Gloss BS, RA, Scolyer VA, Heinzelmann-Schwarz L, Scurr A, Defazio Williams ED, Y, Zeng Henshall CK, NF, Hacker Quinn DI, Watts SM, Sutherland RL. The E3 ubiquitin ligase for factor EDD is an adverse prognostic and epithelial ovarian cancer serous in vitro. cisplatin resistance modulates Br J Cancer SR,Oakes Rogers RL, MJ, Ormandy Naylor of mammaryCJ. gland regulation Prolactin development. Neoplasia Database Protein - Target Biodata Implication P. E, H, Holzer Painsipp Herzog in the Y2 receptors of neuropeptide-Y on emotional, effects of immune stress and social behavior of mice. locomotor Neuropharmacology Edelsbrunner ME, E, T, Painsipp Wultsch H, Holzer N, Herzog Singewald RO, Tasan and depression- anxiety-like Reduced P. Y Y4 behavior in neuropeptide related mice. knockout receptor Oakes SR,Oakes Naylor MJ, Asselin-Labat ML, HN, M, Hilton Gardiner-Garden KD, Blazek MA, Chodosh LA,Kazlauskas M, Pritchard PL, JE,Pfeffer GJ, Visvader Lindeman Ormandy CJ. factor The Ets transcription fate. Elf5 specifies mammary alveolar cell Genes Dev Behav U, Chinn R, Piper K, W, Raza Palendira G, Machado L,Pratt Bell A, Khan N, Hislop R, Steyn Rickinson AB, Buckley CD, AD, Selective of virus- accumulation Moss P. with unique homing specific CD8+ T cells phenotype within the human bone marrow. Stanic D, Paratcha G, Ledda F, Herzog H, Sue N, Jack BH, Eaton SA, Pearson RC, Tran BN, Nguyen ND, Eisman JA, Nguyen Kopin AS, Hokfelt T. Peptidergic influences Funnell AP, Turner J, Czolij R, Denyer G, TV. Association between LRP5 on proliferation, migration, and placement Bao S, Molero-Navajas JC, Perkins A, polymorphism and bone mineral density: a of neural progenitors in the adult mouse Fujiwara Y, Orkin SH, Bell-Anderson K, Bayesian meta-analysis. BMC Med Genet forebrain. Proc Natl Acad Sci U S A 2008; Crossley M. Targeted disruption of the 2008; 9:55. 105:3610-5. basic Kruppel-like factor gene (Klf3) Trapp EG, Chisholm DJ, Freund J, Boutcher reveals a role in adipogenesis. Mol Cell Biol Stockli J, Davey JR, Hohnen-Behrens C, SH. The effects of high-intensity 2008; 28:3967-78. Xu A, James DE, Ramm G. Regulation of intermittent exercise training on fat loss Glut4 Translocation by the Rabgap Sutherland RL, Sergio CM, Anderson LR, and fasting insulin levels of young women. As160/Tbc1d4. Role of Phosphorylation Inman CK, Butt AJ, Musgrove EA. Int J Obes (Lond) 2008; 32:684-91. and Membrane Association. Mol Estrogens, cell proliferation and breast Tumes DJ, Wong AC, Sewell WA, McColl Endocrinol 2008; 22:2703-2715. cancer. In: Melmed S, Rochefort H, SR, Connolly A, Dent LA. Differential rates Chanson P, Christen Y, editors. Research Stone ML, Walker JL, Chisholm D, Craig of apoptosis and recruitment limit and Perspectives in Endocrine ME, Donaghue KC, Crock P, Anderson D, eosinophil accumulation in the lungs of Interactions: Hormonal Control of Cell Verge CF. The addition of rosiglitazone to asthma-resistant CBA/Ca mice. Mol Cycle. Berlin Heidelberg: Springer-Verlag; insulin in adolescents with type 1 diabetes Immunol 2008; 45:3609-17. 2008. p. 123-138. and poor glycaemic control: a randomized- Turner N, Heilbronn LK. Is mitochondrial controlled trial. Pediatr Diabetes 2008; Suttor VP, Biankin AV, Chin WK, Chow C, dysfunction a cause of insulin resistance? 9:326-34. Biankin SA, Merrett ND, Alrubaie A. Trends Endocrinol Metab 2008; Pancreatic anomaly with multiple Styrkarsdottir U, Halldorsson BV, 19:324-30. endocrine neoplasia type 1: a case of Gretarsdottir S, Gudbjartsson DF, Walters pancreas divisum and hemosuccus Turner N, Li JY, Gosby A, To SW, Cheng Z, GB, Ingvarsson T, Jonsdottir T, pancreaticus (santorinirrhage). Pancreas Miyoshi H, Taketo MM, Cooney GJ, Saemundsdottir J, Center JR, Nguyen TV, 2008; 36:314-5. Kraegen EW, James DE, Hu LH, Li J, Ye Bagger Y, Gulcher JR, Eisman JA, JM. Berberine and its more biologically Christiansen C, Sigurdsson G, Kong A, Swarbrick A. Review of: Tumour invasion available derivative, dihydroberberine, Thorsteinsdottir U, Stefansson K. Multiple and metastasis initiated by microRNA-10b inhibit mitochondrial respiratory complex I: genetic loci for bone mineral density and in breast cancer. Breast Cancer Online a mechanism for the action of berberine fractures. N Engl J Med 2008; 2008; 11. to activate AMP-activated protein kinase 358:2355-65. Swarbrick A, Roy E, Allen T, Bishop JM. Id1 and improve insulin action. Diabetes 2008; Su YC, Rolph MS, Hansbro NG, Mackay cooperates with oncogenic Ras to induce 57:1414-8. CR, Sewell WA. Granulocyte-macrophage metastatic mammary carcinoma by van der Poorten D, Milner KL, Hui J, colony-stimulating factor is required for subversion of the cellular senescence Hodge A, Trenell MI, Kench JG, London R, bronchial eosinophilia in a murine model of response. Proc Natl Acad Sci U S A 2008; Peduto T, Chisholm DJ, George J. Visceral allergic airway inflammation. J Immunol 105:5402-7. fat: a key mediator of steatohepatitis in 2008; 180:2600-7. Tan MJ, Ye JM, Turner N, Hohnen-Behrens metabolic liver disease. Hepatology 2008; C, Ke CQ, Tang CP, Chen T, Weiss HC, 48:449-57. Gesing ER, Rowland A, James DE, Ye Y. Viardot A, Heilbronn LK, Herzog H, Antidiabetic activities of triterpenoids Gregersen S, Campbell LV. Abnormal isolated from bitter melon associated with postprandial PYY response in insulin activation of the AMPK pathway. Chem sensitive nondiabetic subjects with a Biol 2008; 15:263-73. strong family history of type 2 diabetes. Int J Obes (Lond) 2008; 32:943-8. I I I I 78 PUBLICATIONS IIII 79 PUBLICATIONS Semin 2008; Obes Rev 2008; 8:384-98. Pain 2008; 22:1200-12. 2008; 19:452-8. Cell Metab Cell Biochem Biophys Res Commun Biochem Biophys Res Yazdi M, Ahnmark A, L, William-Olsson Yazdi M, Wedin N, Osla F, Snaith M, Turner Asztely AK, A, Elmgren Bohlooly YM, of The role D. S, Linden Schreyer glycerol-3-phosphate mitochondrial lipid and in regulating acyltransferase-1 fed diet in high-fat homeostasis glucose mice. 2008; 369:1065-70. central Insulin resistance: T. J, Kraegen Ye 2007 mechanisms. The and peripheral Report. Conference Stock 2008; 9:30-4. M, Hoehn KL, Ramm G, Larance MF, Yip MC, Guilhaus M, James DE.Wagner phosphorylationCaMKII-mediated of the for is required Myo1c myosin motor in translocation GLUT4 insulin-stimulated adipocytes. Cell Dev Biol Cell Watt MJ, van Denderen BJ, Castelli LA, BJ, Castelli MJ, van Denderen Watt CR,Bruce Hoy AJ, Macaulay EW, Kraegen L, BE. lipase Kemp Adipose triglyceride muscle lipid of skeletal regulation and insulin responsiveness. metabolism Endocrinol Mol A, Zengin H, Baldock PA. Herzog IP, Wong of bone mass. regulation Central M, Vissel B, Randic DH, Royle G, Kolaj Youn of primary afferent LTP M. Enhanced receptor in AMPA neurotransmission GluR2-deficient mice. 136:158-67. J Cell 2008; Am J Physiol Immunity 2008; 294:E861-9. 2008; 13:5304-15. 2008; 68:5628-38. 2008; 42:1219-25. 2008; 182:171-84. Endocrinol Metab R, BG, Hooper Stuckey Attewell JP, Walsh Eisman V, S, Ferrari Fletcher JD, MJ, Wark disease of bone: of Paget's JA. Treatment a survey in Australia. practice clinical of Bone TH, Dean JL, Y, Millar EK, Tran Wang CJ,McNeil CM, Burd Henshall SM, Utama FE, Witkiewicz A, H, Sutherland RL, Rui Knudsen KE, D1b is Knudsen ES. Cyclin to in response regulated aberrantly challenge and promotes therapeutic antagonists. estrogen to resistance Res Cancer Vogelzang A, C. King Vogelzang modulatory The in the capacityof interleukin-21 disease. pathogenesis of autoimmune Biosci Front Vince JE, Chau D, Callus B, Wong WW, JE, Callus B, Wong Vince Chau D, McKinlay M, Hawkins CJ, Schneider P, CA,Benetatos SM, Chunduru SK, Condon DL, G, Brink R, J. TWEAK- Silke Vaux Yeoh lysosomal FN14 signaling induces to complex of a cIAP1-TRAF2 degradation TNFalpha. to tumor cells sensitize Biol J, Sprent D, A, HM, Yu McGuire Vogelzang Mackay CR, King C. role A fundamental of T in the generation interleukin-21 for helper cells. follicular 29:127-37. Siebel AL, GD, GJ, Cooney Wadley GK,McConell Wlodek ME, JA. Owens insufficiency and reducing Uteroplacental muscle skeletal alters size litter biogenesis in a sex-specific mitochondrial manner in the adult rat.

IIII 81

FINANCIAL HIGHLIGHTS

2004 20052008 2006 2007 $'000 $'000$'000 $'000 $'000 FINANCIAL HIGHLIGHTS FINANCIAL *The figures in 2006 and 2007 have been adjusted to improve the comparability with 2008. the comparability improve to in 2006 and 2007 have been adjusted *The figures Accumulated Surplus Carried Forward Carried Surplus Accumulated 922 308 9,914 11,109 16,571 Net IncomeNet Forward Surplus Brought Accumulated Reserve Program Research from/(to) Transfer Endowment Reserve from/(to) Transfer Expense Reserve Infrastructure from/(to) Transfer (583) 1,486 - (1,110) (582) 922 (107) (1,726)3,028 - 23,074 6,350 601 2,222 (11,809) (2,526) 308 (1,552) (3,664) 380 9,914 1,035 1,847 11,109 207 Building Asset Amortisation Depreciation Plant and Equipment Property, Earnings Building Reserve from/(to) Transfer Endowment GrantsEndowment Endowment Fund to direct Donations & Bequests Investments loss on Endowment Fund Unrealised (1,235) (2,178) 1,047 (2,449) - (1,171) - (2,433) 1,047 (1,171) (2,390) - (1,353) (1,171)1,700 - 463 1,011 2,181 2,589 1,250 (1,180) 1,047 - (1,189) - 1,047 745 - 10,965 - 5,393 (7,407) 2,210 3,953 Total Operating Expenses Operating Total 24,099 27,257 34,213 37,493 44,798 Administration and Information Technology Information CostsExpenditures*and Remuneration Research Administration Building and Scientific Operations 5,331 2,394 2,931 3,913 3,771 9,377 27,337 4,935 4,571 5,879 7,640 14,879 17,377 21,983 23,621 1,891 2,378 2,438 2,461 2,753 Total Operating Income Operating Total 24,346 30,025 49,114 41,610 46,719 Income Statement Income Garvan Institute of Medical Research of Medical Garvan Institute IIIIIIIII Grants Reviewed Grants Peer GrantsNHMRC Other FoundationOther CollaborationsNSW Government Grant Research Government GrantCommonwealth Income Commercial Garvan Other 9,159 6,222 6,865 8,184 8,530 4,689 1,671 2,343 2,562 3,817 18,695 12,080 13,832 16,682 9,244 1,289 4,811 1,269 2,043 4,091 2,714 - 1,068 2,880 481 200 655 3,720 - 12,174 4,700 4,050 2,579 2,774 2,916 3,543 4,063 1,193 4,026 - Garvan Instititute of Medical Research 2004 2005 2006 2007 2008 Balance Sheet $'000 $'000 $'000 $'000 $'000

Current Assets 3,672 5,632 18,236 19,405 30,012 Property, Plant and Equipment 41,540 40,022 40,903 45,160 60,085 Investments at Market Value 9,903 11,630 20,536 26,008 16,441 Total Assets 55,115 57,284 79,675 90,573 106,538

Current Liabilities* 2,949 3,547 6,900 8,343 7,860 Provisions 2,061 2,457 3,069 3,042 3,545 Borrowings 6,000 6,000 - 4,179 18,144 Total Liabilities 11,010 12,004 9,969 15,564 29,549

Accumulated Surplus 922 308 9,914 11,109 16,571 Reserves 43,183 44,972 59,792 63,900 60,419 Total Net Funds 44,105 45,280 69,706 75,009 76,990

*The figures in 2006 and 2007 have been adjusted to improve the comparability with 2008. I I I I 82 FINANCIAL HIGHLIGHTS IIII 83 FINANCIAL HIGHLIGHTS 2004 20052008 2006 2007 $'000 $'000$'000 $'000 $'000 Net AssetsNet 130 129 507 78 109 Accumulated Funds Carried Forward Funds Accumulated By: Represented AssetsLiabilities 130 129 78 109 1,391 197 182 251 311 507 (67) (53) (173) (202) (884) Total Grants Total 8,641 13,527 6,027 2,921 3,088 General ResearchResearch General Specific Endowment Funds926 567 850 871 750 3,762 1,493 1,691 3,067 1,104 1,250 745 10,965 2,210 3,953 Accumulated Funds Prior Years Prior Funds Accumulated Institute: to Grants for Available Funds 3,051 3,217 189 13,605 130 6,136 9,148 129 78 109 Public Awareness ProgramPublic Awareness RaisedNet Funds (56) (66) 2,862 3,087 - 13,476 6,058 - 9,039 - Fundraising ExpensesFundraising (642) (607) (1,018) (1,184) (1,114) Total Income Total 10,153 14,494 7,242 3,560 3,760 Statement of Funds Statement Garvan Research Foundation Garvan Research Donations & Pledges& Donations EventsBequests and Other incomeInterest 6,861 3,276 2,524 3,826 4,961 17 3,132 1,847 42 105 263 266 332 409 10,315 4 928 21 25 55 Garvan Institute of Medical Research 384 Victoria Street Darlinghurst Sydney NSW 2010 Australia T +61 2 9295 8100 F +61 2 9295 8101 www.garvan.org.au

Project Manager Alison Heather Design Jason McDonald Photography Penelope Clay

Published April 2009 Copies of the Annual Report can be obtained by contacting: Gabriella O’Neil [email protected] T +61 2 9295 8120 I I I I 84